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shows little or no fluorescence. Reproducd from reference [7]. (No scale bars 
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Figure 3.2. Nanoneedle fabrication method. Gray, green, and yellow coloring 
represents the silicon wafer, silicon dioxide layer, and photoresist layer, 
respectively. The surface of a silicon wafer was first patterned by creating a 
silicon dioxide layer by oxidation (a), applying photoresist (b) and patterning it 
by photolithography (c), transferring the pattern to the silicon dioxide layer by 
oxide etching (d) and leaving behind a hard mask of silicone dioxide after 
removing the photoresist (e). The nanoneedles were then created by anisotropic 
(f) and then isotropic (g) etching. The tips were sharpened by oxidation (h) and 
then the oxide layer was removed (i). ....................................................................... 19 
Figure 3.3. Scanning electron microscopy images of nanoneedles. (a) Section of an 
array of nanoneedles. (b) Further magnified view of a nanoneedle showing its 
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Figure 3.5. Representative fluorescence microscopy imaging of cell monolayers after 
puncture with nanoneedles. Brightfield (a), green fluorescence (b), and red 
fluorescence (c) images of DU145 cells are shown after puncture loading using 
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propidium iodide staining, which is a marker for non-viable cells. Scale bars are 
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Figure 3.6. The percentage of intact (gray) and viable (white) cells at 0 and 24 h with 
and without the puncture loading. Control cells were untreated. Treated cells 
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confocal microscopy (z-stack). (a) Untreated cells. (b) Cells punctured by 
nanoneedles, with nanoneedles still in place. Cells were stained with Hoechst 
(blue) and CellMask orange (red) to label the nucleus and cell membrane, 
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Intracellular delivery of macromolecules is crucial for the success of many 
research and clinical applications. Especially, increasing interest in delivery of 
pharmaceutical agents requires effective methods to transport drugs across the cell 
membrane. Intracellular delivery methods, such as lipofectamine, electroporation, and 
microinjection, have been developed and used for many years due to the simplicity of the 
method and the efficiency of intracellular uptake. However, these conventional methods 
are still inadequate for several applications because of the issues associated with toxicity, 
low-throughput, and/or difficulty to target certain cell types. In this study, we developed 
and evaluated new high-throughput intracellular delivery methods for the efficient 
delivery of macromolecules while maintaining high cell viability. 
First, we studied the feasibility of using an array of nanoneedles to physically 
make transient holes in cell membranes for intracellular delivery. The array of 
nanoneedles was fabricated to have sharp tip diameters in the range of tens of nanometers 
and contain 250,000 needles per array. Two delivery methods, puncture loading and 
centrifuge loading, were developed and assessed for the intracellular uptake of 
fluorescent molecules in human prostate cancer cells. For each method, we studied the 
effect of various experimental parameters on cell viability and delivery efficiency of 
fluorescent molecules. We observed effective intracellular delivery of up compounds as 
large as 500 kDa FITC-dextran molecules using the puncture loading method and 
determined the dependence of delivery efficiency and viability on puncture force and 
time. We also examined the effect of nanoneedle type, centrifugal force, and time on the 
viability and intracellular uptake in centrifuge loading. In both methods, high-throughput 
intracellular delivery was feasible by creating transient holes in cell membranes with the 
sharp tips of the nanoneedles. 
The second physical intracellular delivery method we studied was a novel 
microfluidic device that created transient holes in the cell membrane by mechanical 
deformation and shear stress to the cell. We observed efficient delivery of fluorescent 
molecules to prostate cancer cells and leukemia cells and studied the effect of device 
 xix 
design and flow pressure on the delivery efficiency compared to data in the literature. 
Furthermore, we observed the delivery of proteins, which are similar to the size of other 
pharmaceutical proteins. We accounted for cell loss and clogging in the constriction 
channels of the microdevices and determined the true loss of cell viability associated with 
this delivery method by accounting for all cells introduced into the device.  
Lastly, we investigated the possibility of intracellular delivery using nanoparticles 
on a target cell line. We screened for suitable nanoparticle materials among a number of 
candidate materials based on maintaining cell viability of leukemia cells and on plasmid 
transfection efficiency. Mesoporous silica/poly-L-lysine nanoparticles were selected for 
further intracellular delivery study based on cell viability and intracellular delivery 
capability. We demonstrated the co-delivery of protein and plasmid by encapsulating into 
and coating onto the surface of the nanoparticles, respectively, which would be 
advantageous for certain therapeutic strategies.  
In summary, this work introduced two new intracellular delivery methods 
involving nanoneedles and novel nanoparticles, and provided an early, independent 
assessment of microfluidic delivery, showing the strengths and weaknesses of each 
method. With continued research, these methods can be further optimized for a number 







Delivery of drugs and molecules into cells in an effective and efficient manner is 
of widespread interest and studied extensively due to its many applications in biology and 
medicine. Effective intracellular delivery of pharmaceutical agents, such as proteins, 
antibodies, enzymes, plasmids, and drug-loaded nanocarriers, can be utilized for the 
treatment of cancer, genetic disorders, and other acquired diseases by targeting the site of 
genetic mutation, stimulating the immune response, or modifying cellular information [1, 
2]. For these pharmaceutical agents to be therapeutically active, they often need to be 
delivered intracellulary inside cytoplasm or onto the nucleus [3]. 
The major barrier for the delivery of these pharmaceutical agents is the cell 
membrane, which has a bilayer structure from phospholipids and is lipophilic in nature. 
While molecules can enter the cytoplasm by the endocytic pathways, they may end up 
within endosomes and be degraded by lysosomal enzymes. Only portion of molecules are 
likely to end up in cytoplasm and there may be other barriers such as cytoplasm 
trafficking and nuclear membrane, for the delivery to be successful [4]. Instead, number 
of methods are developed to make transient holes on the cell membrane by exerting 
external forces but will compromise the viability of the cells. Thus, an ideal intracellular 
delivery method should have following features; protection of pharmaceutical agents, 
specific targeting, prevention of non-specific interaction with other components, reaching 
required intracellular dose, low toxicity, and cost-effectiveness [5]. 
There are a number of biological, chemical, and physical methods that have been 
developed and are commercially available for intracellular delivery in laboratory settings. 
Although these systems are widely used and highly efficient, there are a number of 
drawbacks with these systems, such as low throughput and toxicity. To address 
limitations of previously developed methods, we studied three alternative intracellular 
delivery techniques, using nanoneedles, a microfluidic device, and nanoparticles, for the 
delivery of macromolecules, protein, and plasmid. In each chapter, the intracellular 
delivery techniques used are characterized and optimized for high viability and uptake of 
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fluorescent molecules by varying experimental parameters. Once the uptake of 
fluorescent molecules of various sizes has been demonstrated, the feasibility of delivery 
of functional protein and plasmid has been further investigated, which usually requires 
the delivery not only inside cytoplasm but also onto the nucleus. 
The first part of the study is on a nanoneedle-mediated intracellular delivery 
method. Among many other delivery methods, microinjection is known as a universal 
intracellular delivery mechanism for its capability to by-pass both physical and chemical 
barriers. However, there is a major drawback to the method as the injection is done 
manually at the single cell level [6]. In order to address the limitation of microinjection, 
we propose an alternative method using multi-needle arrays of nanoneedles which can 
achieve high-throughput delivery of molecules and will resemble the delivery mechanism 
similar to that of microinjection. Broad experience with microneedles in our lab 
demonstrated the possibility of drug delivery in skin and eyes as well as preliminary 
intracellular delivery using solid microneedles [7]. Nanoneedles, fabricated out of silicon 
with high needle density and very sharp tip diameter, in the nanometer range, are utilized 
in two different loading techniques; centrifuge and puncture loading. Uptake of 
fluorescent molecules and cell viability in human prostate cancer cells are quantitatively 
measured at varying parameters, such as force and time applied.  
Two other intracellular delivery methods, microfluidic device and nanoparticles, 
are explored as nanoneedle-mediated intracellular delivery works well with adherent cells 
but showed poor result with suspension cells. The microfluidic device consists of tens of 
constrictions channels to squeeze the cells and create transient holes in the cell membrane 
for the diffusion of molecules into the cell [8]. The method is tested in different cell lines, 
prostate cancer cells and leukemia cell lines, which are suspension cells in nature. We 
studied the effect of varying parameters, such as constriction width and pressure, on the 
cell loss and viability after the treatment.  
Nanoparticles can be made of many different materials, including polymers, 
inorganic metals, quantum dots, etc., and delivered intracellularly by endocytic pathways 
and/or ligand-receptor interaction [9]. We tested nanoparticles made of different 
materials for DNA delivery to a leukemia cell line for high cell viability and high GFP 
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2.1 Intracellular delivery 
Intracellular delivery has been an area of interest to many, especially in the 
medical and pharmaceutical field. Intracellular delivery is the process of delivering the 
molecules or therapeutic agents to cellular or organ compartments across the cell 
membrane. Despite years of research and the existence of some already established 
methods, there is still much on-going research on new intracellular delivery methods for 
more efficient and effective delivery method. 
2.1.1 Barriers 
The cell membrane, which has a bilayer structure from phospholipids and is 
lipophilic in nature, is the major barrier for intracellular delivery. Direct intracellular 
delivery of compounds from the surroundings is restricted by cell membrane, such that 
macromolecules, such as proteins and plasmids, cannot be delivered without the active 
transport mechanism [3]. Under certain conditions, molecules can enter the cytoplasm by 
the endocytic pathways by receptor-mediated endocytosis [4]. However, molecules taken 
in by endocytosis may end up within endosomes and can be degraded by lysosomal 
enzymes [10]. Thus, only a small portion of molecules entering cytoplasm may be 
unaffected. The small portion of unaffected molecules in the cytoplasm may face other 
barriers, such as cytoplasm trafficking in the dense meshwork of the cytoskeleton and the 
membrane of target organelles. Therapeutic agents and molecules often need to be 
delivered to the specific organelles, such as nuclei, mitochondria, and endoplasmic 





Intracellular delivery has been studied extensively for many years due to the 
number of possible applications. Some of the prevalent applications and delivery agents 
will be discussed in more detail below. 
2.1.2.1 Imaging and tracking 
Imaging and tracking in cells is important in understanding the complex system of 
cells; how cells behave, carry out functions, and respond to changes in the surroundings. 
While there are number of fluorescent sensors and proteins available for use, quantum 
dots have several characteristics that are more desirable for imaging and tracking; 
composition- and size-dependent absorption and emission, long fluorescence lifetime, 
and surface functionalization [11]. Using little amount of quantum dots and different 
surface functionalization, quantum dots can label live cells, the specific organelles, and 
surface proteins for imaging and tracking. For targeting and labeling, the quantum dots 
need to be delivered into the cytoplasm and/or nucleus without being trapped in the 
endocytic pathway [11]. Due to the size of quantum dots, they cannot cross the cell 
membrane barrier and need to be intracellularly delivered by methods, such as 
electroporation, microinjection, and lipofection [12, 13]. A study showed that a number 
of delivery methods, with the exception of microinjection, are not able to easily deliver 
quantum dots without forming aggregation or getting trapped in the endosomes [14]. 
Another limitation is the difficulty of washing away excess quantum dots. 
2.1.2.2 Cellular engineering 
Cellular engineering is an emerging area of studying the role of engineering in 
basic cell biology and making products out of living cells [15]. One well-known example 
of cellular engineering is the generation of induced pluripotent stem cells (iPSCs) from 
adult human fibroblasts by four transcription factors [16]. With number of possible 
applications using stem cells, the cell engineering of stem cell is being studied 
extensively [17]. Two cell engineering possibilities are the direct differentiation from 
pluripotent stem cells and direct conversion from other somatic cells [18, 19]. Finding the 
right transcription factors and protocol for desired state is crucial, but delivery of these 
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transcription factors in efficient and safe way is also important for the further use of 
generated stem cells. In addition, choosing a right delivery method that will not alter the 
stem cell behavior or identity is of importance.  
2.1.2.3 Gene therapy 
Gene therapy is the delivery of genetic materials as a drug to stem cells or 
immune cells for the treatment of cancer, genetic disorder, and other acquired diseases. 
With increasing amount of research on genome editing tools, such as zinc finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered 
regularly interspaced short palindromic repeats (CRISPRs), the area of gene therapy is 
growing [20-22]. These restriction enzyme pairs can be designed to target and induce 
double strand break at specific DNA sequence. The cell can respond with two repair 
mechanisms, non-homologous end joining and homology directed repair, to introduce the 
donor template, which encodes the correct DNA sequence, at the site of double strand 
break. By delivering restriction enzymes, either as a protein or a plasmid encoding these 
proteins, with a donor template, gene correction at the targeted site can be accomplished 
[23]. 
Gene therapy can be completed by efficient intracellular delivery of therapeutic 
agents to immune cells or stem cells, which can be treated ex vivo and transplanted back 
to the patient to treat cancer, genetic disorder, and other acquired diseases [1, 2, 24]. 
Manipulation of immune cells, like natural killer (NK)-cells and T cells, have been 
considered as the possible cancer immunotherapy after years of studying immune 
responses against tumors [25-27]. In recent years, some successes of treating leukemia 
with genetically modified T cells, to recognize a variety of tumor-associated antigens, 
have been demonstrated [28-30]. Stem cells can also be used as a possible treatment for 
genetic disease due to stem cells’ ability to differentiate into several tissues. 
Mesenchymal stem cells (MSCs) can differentiate into mesenchymal tissues and have 
been investigated to treat patients with heart diseases and autoimmune diseases [31, 32]. 
Hematopoietic stem cell (HSC) transplantation is known as one of the effective 
treatments available for the sickle cell disease and was first used 25 years ago [33]. 
Although HSCs are rare in the body, the potential of a single HSC to rebuild the entire 
 7 
blood system after the transplantation has been demonstrated [34, 35]. Other types of 
stem cells, endothelial progenitor cells and neural stem cells, also have potential to 
differentiate into endothelial and neural cells lineage and have been investigated for the 
gene therapy [36]. 
2.2 Current intracellular delivery techniques 
For any applications to succeed, the construction of working therapeutic agents 
will be necessary along with the good gene delivery methods. Thus, an ideal intracellular 
delivery method should have the following features; protection of pharmaceutical agents, 
specific targeting, prevention of non-specific interaction with other components, reaching 
required intracellular dose, low toxicity, and cost-effectiveness [5].  A number of 
intracellular delivery methods are available and used in many laboratories for different 
applications. Three main categories of the intracellular delivery methods are biological, 
chemical, and physical methods and will be discussed in more details below. 
2.2.1 Biological methods 
Biological method involves the use the viral vectors as a carrier and is most 
commonly used in laboratories for the delivery of plasmid. Viral vectors, such as 
lentivirus, retrovirus, adeno-associate and adeno-derived vectors, have been used to 
introduce the therapeutic gene into the cells by a process called transduction [37]. Viral 
vectors have been used widely due to the stable gene expression and the high efficiency 
as virus has natural tendency to infect the host cell and replicate [38]. In addition, the 
ease of design and use of viral vectors is one of the advantages of the method. However, 
number of problems has limited the further use of viral vectors in clinical applications. 
The packaging capacity of plasmid DNA is limited and the preparation in a large-scale is 
difficult and expensive. Number of potential problems in clinical application also 
includes the risk of mutagenesis, induction of immune responses, and pathogenic risk [5, 
24, 39, 40]. Due to these problems that may raise safety concerns with biological 




2.2.2 Chemical methods 
 In an effort to move away from viral vectors, development of synthetic vectors 
has been of interest. The non-viral vectors are relatively simple for quantitative 
production and are safer alternative due to low host immunogenicity [41]. The 
therapeutic agents can be encapsulated into the cationic lipids or synthetic polymers, such 
as polyethylenimine (PEI), and polylactic acid (PLA), to be delivered across the cell 
membrane. 
Lipofection, a transfection mediated by liposomes, is one of the most widely used 
chemical methods. Liposomes are formed by a self-assembly of cationic lipids, which 
have polar heads and non-polar tails. The positive charge present in these structures 
allows the interaction with negatively charged plasmids. Plasmids can bind to the surface 
or can be placed inside the aqueous phase of liposomes to form lipoplexes for delivery 
[42]. Similarly, polyplexes can be formed by plasma binding on polymers [43]. Lipoplex 
and polyplex can be taken inside the cell by endocytosis and destabilized inside the 
cytoplasm to release DNA [5, 44]. Since the method is simple to use and safe, many 
products are commercially available to be used for cell transfection. Despite the use of 
lipofection in many laboratories, there are major limitations of low delivery efficiency 
and toxicity associated the lipoplexes. The lipofection suffers from poor transfection 
efficiency since the uptake across the cell membrane via endocytosis is low, which could 
be order of magnitude lower than the efficiency of viral vectors. In addition, lipoplex are 
recognized as foreign and trigger the production of cytokines once taken inside the cell 
[45]. The toxicity of liposome may be questionable for the use of lipofection in gene 
therapy and have been studied to develop safer cationic lipids. 
2.2.3 Physical methods 
Physical methods use different types of external forces to temporarily disrupt the 
cell membrane and have been investigated in the recent years due to the advantage of 
delivering the therapeutics agents without encapsulation in lipids or polymers, which 
reduces the immune response, the toxicity associated with polymers, and the modification 
of therapeutic agents [45-47]. Although a lack of protection might result in DNA 
degradation and low efficiency, minimal immune response makes the physical methods a 
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desirable alternative for gene therapy. Some widely used physical methods are discussed 
in details below.  
2.2.3.1 Electroporation 
Electroporation is one of the widely used physical methods for cell transfection 
and has been known as the standard for plasmid delivery. When the short electrical pulse 
is applied to the cells, cell membrane is transiently disrupted and molecules can enter the 
cytoplasm by diffusion and electrophoresis before the membranes reseal [48]. The 
method has been used in various applications, such as cancer treatment, DNA 
transfection and gene therapy, and proven to be effective in both in vivo and in vitro 
treatment [49, 50]. Extensive study on the method has led to high percentage of cell 
permeabilization with low cell death using the optimum conditions. However, due to the 
differences between different types of cells, optimization of different parameters, such as 
pulse electric field intensity, electrical pulse type, electropulsation buffer conductivity, 
and electroporation temperature, is required for different cell types [5]. Cell lines with 
large heterogeneity in cell size or non-spherical orientation are difficult to optimize due 
to inverse correlation between cell size and the external field for permeabilization [1]. 
Electroporation of cells in suspension also requires a voltage up to 1 kV and such high 
voltage can affect the stability of plasmids. Due to vulnerability of cells after the 
treatment, post-pulse manipulations of cells are also important to maintain the high cell 
viability and to maintain the proper biological functions, especially for the application of 
gene therapy. 
2.2.3.2 Ultrasound 
Ultrasound has been exploited in number of biological application, as a sensor, an 
acoustic microscopy, and a method for intracellular delivery of fluorescent molecules, 
genetic materials, and chemotherapeutic compounds by transient mechanical disruption 
of cell membranes [51]. It is assumed that the acoustic cavitations or acoustically-induced 
bubble activity causes cell membranes to transiently enhance the permeability and 
increase the efficiency of intracellular delivery [52-55]. Effective in vitro delivery of 
chemotherapeutic agents, such as BH3 peptides and doxorubicin, encapsulated in 
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microbubbles or micelles using ultrasound has been demonstrated [56, 57]. Despite the 
promising results of ultrasound, there are number of disadvantages to the method. The 
application of this method is limited to a specific tissue type of anatomical region and 
requires complex equipment [58]. Effect on cell viability depends on the acoustic 
intensity and has been of concern due to the damage on the cell membrane during the 
ultrasound. The effect of ultrasound is also non-homogeneous and not consistent since 
same condition can result in various results in terms of membrane poration and cell 
viability due to difference in the cell structure [59]. 
2.2.3.3 Fluid mechanical delivery 
Fluid mechanical delivery employs the physical force generated by fluid motion 
for permeabilization of the cell membrane and delivery of macromolecules. Increase in 
membrane tension due to shear forces is believed to induce the cell membrane poration 
[60, 61]. Intracellular delivery of macromolecules has been demonstrated by directly 
applying shear forces to cells by rapid flow through small-gauge hypodermic needles, 
called syringe loading [62]. Using microchannel devices, shear-induced loading of cells 
with fluorescent molecules of different sizes has been studied [63]. The effect of varying 
flow conditions, such as shear forces and time, and device design on intracellular delivery 
and cell viability have been studied. Recent work on the new device with constriction 
channels to deform and shear cells has demonstrated the delivery of various fluorescent 
molecules, proteins, and nanotubes on number of different cell types [8]. While the 
delivery technique is high throughput method, easy to use and relatively inexpensive, the 
delivery is mainly limited to cytoplasm and further studies need to be conducted to 
understand the delivery mechanism. 
2.2.3.4 Magnetofection 
Magnetofection is a delivery technique utilizing magnetic fields to concentrate 
nanoparticles containing nucleic acids into the cells [64]. Particles are chosen based on 
the following properties; functionality for association with nucleic acid, magnetic 
properties to react under certain magnetic force, physical and chemical stability, and 
biocompatibility [65]. These particles can be associated with nucleic acids, such as DNA, 
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and RNA, and concentrated on the target cell by magnetic field. The uptake of these 
particles is accomplished by endocytosis and the nucleic acids can be released in the 
cytoplasm [66]. The method has shown promising results in vitro and in vivo studies but 
further studies on the effect of magnetic field on the cellular level and plasmid are to be 
done. 
2.2.3.5 Gene gun 
Gene gun is a technique first developed in 1987 for the delivery of nucleic acids 
into the plant cells using high-velocity microprojectiles [67]. Also known as a biolistic or 
particle bombardment, the technique accelerates the particles, heavy metal particles 
coated with plasmid DNA, by pressurized gas or electric discharge to penetrate into cells 
and release DNA for transfection. The technique was utilized for mammalian cells 
starting in the early 1990s [68]. Delivery of plasmid has been demonstrated in DRG 
neurons and in C. elegans [69, 70]. The technique can be used in vivo for delivery of 
DNA vaccine to skin or exposed tissue [70, 71]. Some limitations of this technique is that 
the cells need to be firmly attached to the substrate to withstand the force of gold 
projectiles and that use of heavy metals can be toxic to the cells or expensive to use [72]. 
2.2.3.6 Microinjection 
Microinjection is well-known method that has been used to inject molecules into 
the cells and is known as a universal intracellular delivery mechanism due to its 
capability to by-pass both physical and chemical barriers. The microinjection system is 
composed of a glass needle of outside diameter about 0.5 to 1 µm, a microinjector for 
suspension cells, and a positioning device to control the micropipette movement. The 
needle, containing a fluid of genetic material, is precisely controlled by a 
micromanipulator using inverted microscope for visual control. Once needle is placed on 
top of the target cell, hydrostatic pressure is applied to inject the material [6, 48]. Since 
materials by-pass the cell membrane and are directly entered to the cells, there is little or 
no degradation of materials or diffusion limitations and the method is very effective and 
reproducible. However, there are number of disadvantages to the method. Since the 
injection is controlled by the injection time and pressure, the volume of the materials 
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entered is difficult to precisely control and the clogging of the micropipette can occur 
over time. Throughput of the method is also of concern since only one cell at a time can 
be injected; i.e. a trained person can only inject up to few hundred cells per day. Due to 
low throughput, microinjection is impractical for gene delivery applications and has 
limited potential. In order to solve this issue of low throughput, many approaches of 
combining the microinjection with microfluidics are being developed [73, 74]. 
2.3 Developing intracellular delivery techniques: Nanobiotechnology 
Nanotechnology refers to a system that has the dimensions of 1 – 100 nm and has 
become an important technology as microelectronic devices become smaller [75]. 
Nanotechnology has offered new tools for studying biology, especially at cellular and 
molecular levels, because of the similarity in dimensions [76, 77]. The advance in 
nanotechnology provided new ways to visualize, manipulate, and characterize cells and 
sub-cellular components inside the cells. In particular, nanoneedle, nanowires, and 
nanoparticles are methods that are similar or used in this thesis and will be further 
discussed below. 
2.3.1 Microfabrication 
Microfabrication is the collection of processes used to make physical objects with 
dimensions in the micrometer to millimeter range. The microfabrication process has been 
used and developed for the semiconductor manufacturing in early years, but has been 
extensively explored in other applications, such as microelectromechanical systems 
(MEMS), microfluidics/lab-on-a-chip, and the extension into nanoscale. In a 
representative process, first, thin film growth or deposition onto the substrate, such as 
silicon, glass, and plastics, is conducted by chemical-reaction-driven or physical 
processes to form one or more thin films for different applications [78, 79]. Afterward, 
the process called photolithography is used to transfer a pattern by coating positive or 
negative photoresist, a photosensitive organic polymer, and exposing under UV light 
[80]. Another method, microcontact printing using a soft polymeric stamp, has been 
introduced and used mainly for non-cleanroom-compatible materials or chemicals [81]. 
Thin film or substrate can be removed according to the transferred pattern by etching 
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process. Using liquid chemicals or plasma, films and substrate can be etched to form 
different structures using either isotropic etching or anistropic etching, or the combination 
of both [82-84]. The fabricated devices are ready to use after washing residual photoresist 
or films and bonding different parts together. Microfabrication process offers many 
advantages in designing new devices by precise control of geometry and dimensions in 
millimeter range. The process is explored in bio-MEMS applications for sensors, lab-on-
chip device, and medical devices [85]. With advancement in the process and the 
increasing interest in nanobiotechnology, there are more possibilities for the device 
designs in biological applications. 
2.3.2 Nanoneedles 
Nanoneedle is one-dimensional nanostructure with nanoscale geometry and high-
aspect ratio, with a diameter of 1 – 100 nm and a length of 1 – 20 µm [86]. One-
dimensional nanostructure, such as carbon nanotubes and boron nitride nanotubes, can be 
fabricated by chemical synthesis to have physical properties appropriate for nanoneedle 
with diameter of 1 – 100 nm [87, 88]. Because of the difficulties to precisely align and 
reliably assemble nanostructure into needle-like probe configuration, other approaches 
are taken to develop nanotube-tipped AFM probes [89, 90]. Alternative method to 
fabricate nanoneedle is nanofabrication techniques, such as focused-ion-beam machining, 
electrochemical fountain pen nanofabrication, and direct-write nanofabrication 
techniques, which usually makes nanoneedle with diameters larger than 100 nm [91-93]. 
Some applications of nanoneedle include the use in biosensors, delivery systems, 
and bio-imaging as these nanostructures can penetrate the cell membrane with minimal 
invasiveness and access the interiors of living cells. Carbon nanotubes have been used as 
a biosensor to detect proteins, antibody-antigen interactions, glucose, and DNA 
hybridization, due to the electrical properties and sensitivity to changes in the 
surrounding environment [94, 95]. Nanotubes can be covalently or non-covalently 
functionalized with proteins and polymers to be more suitable for biological applications. 
Semiconducting boron nitride nanotube has been also used as an electrochemical probe to 
measure signaling processes and electrochemical reactions by coating with layers of 
metal and insulating polymer [96].  
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2.3.2.1 Applications in intracellular delivery 
Nanoneedle has been explored as alternative options for intracellular delivery to 
overcome the barrier of cell membrane with minimal invasiveness and deliver 
macromolecules. Nanoneedle delivery system is composed of three components; an 
individual nanoneedle, a manipulator, and an optical microscope [86]. Fabricated needle 
can be attached to the atomic force microscopy (AFM) probes or incorporated into the 
system similar to the microinjection for manipulation and injection. Delivery can be 
achieved either by loading molecules inside hollow nanotubes or nanopipettes, which is 
similar to microinjection, or by loading molecules on the surface of solid nanoneedles by 
surface functionalization [91, 97-99]. Efficient intracellular delivery by both techniques 
has been demonstrated, but the system still has the same issue as in microinjection of low 
throughput due to the single cell process. Another drawback could be the limited volume 
of loading on nanoneedle, which reduces the number of cells that can be treated per each 
nanoneedle. 
2.3.3 Nanowire 
Nanowire is a nanostructure with aspect ratios of 1000 or more and with the 
diameter in the nanometer range. Various materials, polymers, metal oxides, and silicon, 
have been used for producing nanowires [100-102]. Nanowires can be synthesized in two 
different approaches: top-down and bottom-up. The former approach reduces a bulk 
material to nanowires by lithography or electrophoresis, but is mostly limited to the 
single needle instead of arrays [101, 103]. The latter approach uses surface chemistry to 
grow nanowires on semiconductor materials, using vapor-liquid-solid synthesis, and is 
used more commonly for the synthesis of nanowire arrays [104-106]. The size of the 
nanowires can be controlled precisely by the liquid alloy droplets on the surface.   
Due to nanowires’ physical properties and the materials used for synthesis, 
nanowires have been studied for many different applications in recent years, including 
solar cells, and biological applications. Silicon nanowire arrays have been explored for 
photovoltaic applications for its optical absorption properties, owing to the sub-visible 
wavelength of the wires [107, 108]. Studies in recent years showed the feasibility of 
using nanowires for solar cells, but further studies are being done to increase the solar-
 15 
energy-conversion with different materials and physical properties. In biological 
applications, silicon nanowires have been attractive option for a sensor due to nanowires’ 
high selectivity and sensitivity. Nanowire-based sensors have been explored for the 
detection of real-time biological macromolecules, DNA, cancer markers, and chemical 
detection [109-111].  
2.3.3.1 Applications in intracellular delivery 
Nanowires have been utilized in the recent years for the intracellular delivery to 
deliver molecules in high throughput manner. Carbon nanofibers are grown on a flat 
substrate with the tip diameter less than 100 nm and used for intracellular delivery to 
Chinese Hamster Ovary cells [112]. Vertical silicon nanowires have also been developed 
for the intracellular delivery of proteins and plasmids to neural and neural precursor cells 
[113]. Other materials, such as gallium arsenide and copper oxide, have been used for 
making nanowires [114, 115]. Intracellular delivery using nanowires has demonstrated 
the intracellular delivery with high cell viability. The method also has shown the ability 
to treat many cells at one time. However, most works on nanowires are relatively new 
and still requires further improvement to be reliably used for intracellular delivery. 
2.3.4 Nanoparticles 
Nanoparticles are synthesized particles with the diameters of 1 – 100 nm [116]. 
Using different methods and materials, various types of nanoparticle can be prepared; 
inorganic nanoparticle, polymeric nanoparticles, nanocrystals, nanoboxes, and solid-lipid 
nanoparticle [117-121]. Surface coating of nanoparticles is important for tuning the 
properties, such as stability, solubility, and targeting, based on the application.  
Nanoparticles are explored in optical and electronic field applications as 
nanoparticles’ small size gives rise to unexpected properties [122]. Quantum dots are 
example of nanoparticles with size-dependent optical and electrical properties [123]. 
Because of high quantum yield, high resistance to photobleaching, and broad excitation 
spectra of quantum dots, quantum dots offer many advantages for imaging, labeling and 
sensing over the other fluorescent proteins or labeling techniques [124]. Another field of 
interest for nanoparticles is electronic field. Magnetic nanocrystals, which are iron oxide-
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based particles, have been evaluated for biological applications, including imaging, 
diagnosis and therapy [125]. Improvement in magnetic resonance-imaging by 
internalization of superparamagnetic nanoparticle in mesenchymal stem cells has been a 
promising result [126]. 
2.3.4.1 Applications in intracellular delivery 
Nanoparticles have been used for the intracellular delivery of therapeutic agents 
by either encapsulating inside or coating on the surface of the nanoparticle. By 
modulating polymer characteristics, release of therapeutic agents from nanoparticle can 
be targeted and controlled to desired level for required duration while therapeutic agents 
can be protected from enzymatic degradation [127, 128]. In addition, compared to the 
microparticles, which have diameters of 1 and 10 µm, nanoparticles demonstrated the 
increase in uptake efficiency due to its smaller size [129, 130]. Because of several 
advantages of nanoparticles, there are number of in vivo and in vitro studies on-going for 
drug delivery, such as anticancer drugs, siRNA, and glaucoma drugs [131, 132]. 
Although nanoparticles seem to be an effective intracellular delivery method, the answers 




DEVELOPMENT AND ASSESSMENT OF A HIGH-THROUGHPUT 
INTRACELLULAR DELIVERY SYSTEM USING NANONEEDLES 
 
3.1 Introduction 
Among the many different intracellular delivery methods, microinjection is 
known as a universal delivery mechanism that works in almost all cell types. Since the 
glass pipette is used to directly enter into the cells, the system is advantageous to 
overcome both the physical barrier of the plasma membrane and possibly the nuclear 
membrane and the chemical barrier of diffusion limitations or plasmid degradation  
[133].  These advantages make the microinjection system very effective in drug delivery 
across the cell membrane and desirable to use in other applications. However, the 
microinjection system requires a number of expensive pieces of equipment to visualize 
the cells and needles, to hold the cells in place (for the suspension cells), and to control 
the injection process [134]. In addition, since the injection is done at a single cell level, 
the number of cell injected is very limited and the throughput is extremely low compared 
to most other intracellular delivery methods. We hypothesized that an array of 
nanoneedles can be used for intracellular delivery by adapting the mechanism of 
microinjection to make transient holes in the cell membrane but with increased 
throughput of delivery.  
Microneedles have been studied for years to achieve drug delivery to the eye and 
skin [135, 136]. Using microneedles, preliminary results on intracellular delivery were 
demonstrated in human prostate cancer cells. Very small microneedles (i.e., nanoneedles) 
used in the experiment were 25 µm-tall solid silicon needles assembled in an array of 
160,000 needles and imaged by scanning electron microscopy (Figure 3.1, left). On a 
confluent monolayer of cells, the nanoneedles were inserted briefly and intracellular 
uptake was observed by the uptake of calcein, a cell-impermeant fluorescent marker. The 
green fluorescence image showed the bright fluorescence on the left side, which indicated 
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the uptake of calcein by cells treated with microneedles (Figure 3.1, right). On the right 
side, there was little fluorescence as the cells were untreated.  
 
 
Figure 3.1. SEM image of 25 µm tall solid silicon nanoneedles in an array of 160,000 
(A). The fluorescence image of prostate cancer cells after treatment with the 
nanoneedles (B). The bright fluorescence on the left indicates the uptake of calcein 
after treatment with nanoneedles while the untreated right side shows little or no 
fluorescence. Reproducd from reference [7]. (No scale bars available) 
 
Based on this preliminary result, we investigated the intracellular delivery method 
using a new design of nanoneedles. By reducing the dimensions of the nanoneedles 
further, the nanoneedles can more efficiently target the drug delivery across the cell 
membrane. First, we assessed the feasibility of impalement by nanoneedles across the cell 
membrane and developed the methods of intracellular delivery using the nanoneedles. 
Next, we examined each method by varying experimental parameters to determine the 
range of parameters required for the intracellular uptake and to optimize the delivery 




3.2 Methods  
3.2.1 Cell culture 
 Human prostate cancer cells (DU145, American Type Culture Collection, 
Manassas, VA) were cultured as a monolayer in a humidified atmosphere of 95% air and 
5% CO2 at 37
◦C [137]. RPMI-16490 medium (Cellgro, Herndon, VA) was supplemented 
with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Corning, Palo Alto, CA) and 
1% penicillin/streptomycin (Cellgro). DU145 cells were used as a model cell line because 
they are well characterized and have been used extensively in previous intracellular 
delivery studies [50, 138, 139].  
3.2.2 Nanoneedle fabrication 
 
 
Figure 3.2. Nanoneedle fabrication method. Gray, green, and yellow coloring 
represents the silicon wafer, silicon dioxide layer, and photoresist layer, respectively. 
The surface of a silicon wafer was first patterned by creating a silicon dioxide layer 
by oxidation (a), applying photoresist (b) and patterning it by photolithography (c), 
transferring the pattern to the silicon dioxide layer by oxide etching (d) and leaving 
behind a hard mask of silicone dioxide after removing the photoresist (e). The 
nanoneedles were then created by anisotropic (f) and then isotropic (g) etching. The 
tips were sharpened by oxidation (h) and then the oxide layer was removed (i).  
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Nanoneedles were fabricated using silicon as a structural material since it has 
good mechanical strength and processing capability in the range of microns down to the 
nanoscale [140, 141]. As shown in the schematic in Figure 3.2, a silicon wafer (Siltronic, 
Portland, OR) was covered with a 0.7 µm film of thermal oxide, SiO2, with a TYTAN 
Mini Furnace (Tystar, Torrance, CA) and was patterned using a positive photoresist mask 
(Microposit S1813, Shipley, Marlborough, MA). The etch mask pattern was designed 
with square patterns of 7 µm with an edge-to-edge gap between squares of 3 µm. The 
center-to-center spacing of the spots was 10 µm, which is somewhat smaller than the 
average diameter of DU145 cells in a confluent monolayer (i.e., 15 – 20 µm). Oxide 
etching was performed using an inductively coupled plasma etcher (ICP, Plasma-Therm, 
St. Petersburg, FL) to yield an array of SiO2 spots.  
After oxide etching, anisotropic dry etching of silicon was performed using SF6- 
based gas mixture in the ICP to form 12 µm-tall square pillars under each masked spot. 
Isotropic dry etching of the silicon with an SF6 plasma in the ICP followed, which 
produced tapered tips at the top of each pillar by utilizing under-etching of silicon under 
the etch mask. After removing residual masks by hydrofluoric acid and cleaning with DI 
water, tips were further sharpened to nano-scale sharpness using an oxidation sharpening 
process [142]. The resulting array of nanoneedles was die cut into individual 5 mm x 5 
mm chips using a dicing saw (Advanced Dicing Technologies, Horsham, PA) and 
cleaned with acetone, isopropyl alcohol, and piranha solution, which is a mixture of 
sulfuric acid and hydrogen peroxide. These fabrication methods have been presented in 
greater detail previously [143]. 
3.2.3 Puncture loading 
3.2.3.1 Sample preparation 
DU145 cells were harvested by trypsin/EDTA (Cellgro) and plated on a 35 mm 
cell culture dish (Corning, Tewksbury, MA) or µ-Slide 8-well chambered coverslip 
(ibidi, Martinsried, Germany) 1 - 2 days prior to the experiment. The confluent 
monolayer of cells was washed once with PBS before adding a solution of fluorescent 
molecules: calcein or 70 kDa FITC-dextran prepared in RPMI at a concentration of 100 
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µM, or 500 kDa FITC-dextran (Sigma-Aldrich) prepared at a concentration of 12.5 µM 
to avoid excessive dye sticking to the cell membrane at higher concentration. 
Doubled-sided tape (3M, Saint Paul, MN) was attached to an SEM sample holder 
(Ted Pella, Redding, CA) or a captive female threaded round standoff (McMaster-Carr). 
A 1/16”-thick, deformable adhesive foam tape (Medco Coated Products, Bedford 
Heights, OH) was attached to allow self-correcting of possible non-parallel contact 
between the nanoneedles array and the cell monolayer. A nanoneedle array was mounted 
onto the adhesive foam tape. 
3.2.3.2 Delivery method 
Puncture loading was conducted using an ESM301 motorized test stand (Mark-
10, Copiague, NY), which was used to control the speed of nanoneedle array application 
to cells, the puncture time contacting the cells, and the speed of nanoneedle array removal 
from the cells. Unless otherwise noted, the application and removal speeds were 150 
mm/min and 10 mm/min, respectively, and the puncture time was varied from 1 to 120 s. 
The sample holder to which the nanoneedle array was attached was screwed onto a digital 
force gauge (Series 5 M5-05, Mark-10) in order to control the force of nanoneedle 
puncture, which was varied from 0.1 to 0.5 N. A cell culture dish containing a cell 
monolayers was placed underneath the nanoneedle array for puncture after the cell 
culture medium was replaced with a solution containing fluorescent dye.  
After puncture, the cells were left for 15 min to recover. The cells were then 
washed with PBS four times to remove the extracellular fluorescent molecules, after 
which RPMI with 2.5 µg/ml PI was added to stain non-viable cells 10 min before 
imaging.  
3.2.3.3 Analysis and quantification 
Cells were imaged using an inverted fluorescence microscope (Olympus IX70, 
Olympus, Center Valley, PA). Using cellSense Standard software (Olympus), images 
were taken at 4x magnification and captured using three filters: brightfield, green 
fluorescence, and red fluorescence images for the analysis of cell detachment, uptake of 
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fluorescent molecules, and cell viability, respectively. Sufficient numbers of images were 
taken to create a composite image of the entire area treated by the nanoneedle array. 
The images captured were patched together to form one composite image for each 
of the three filters to show the entire area treated by nanoneedles. The images were then 
analyzed by Adobe Photoshop CS3 (Adobe Systems, Mountain View, CA) to quantify 
uptake and cell viability based on the cells with green and red fluorescence, respectively. 
The fluorescence threshold for identifying a cell as containing a dye was set based on the 
background fluorescence of untreated areas in the images, which served as the sham 
control. The percentage of cells with calcein or FITC-dextran uptake was determined by 
dividing the area with green fluorescence above threshold by the total area contacted by 
the nanoneedle array. The percentage of non-viable cells was similarly determined by 
dividing the area with red fluorescence above threshold by the total area contacted by the 
nanoneedle array and multiplying by the ratio of the nucleus area to the cell area, because 
PI only stains the nucleus of the cell.  
Confocal microscopy imaging was also conducted to visualize the interaction 
between nanoneedles and cells at higher magnification and to further study the process of 
intracellular uptake. The cells were plated on a glass cover slip after trypsinization and 
cultured for 1 - 2 days before imaging. Prior to nanoneedle puncture, the cell nucleus was 
stained with Hoechst 33342 (trihydrochloride, Invitrogen) at a final concentration of 2 
µg/ml for 20 min and the cell membrane was subsequently stained with 1x working 
solution of CellMask orange or green (Invitrogen) for 10 min at 37◦C. Either propidium 
iodide or calcein AM (Invitrogen) was used as an uptake marker, as these dyes are 
fluorescent only intracellularly. Cells were either imaged live or fixed by 4% 
formaldehyde (Sigma-Aldrich). The cell-coated overslip was placed on a microscope 
slide or a sheet of PDMS, punctured with nanoneedles and sealed with nail polish.  
The prepared samples were images using an LSM 700 confocal laser scanning 
microscope (Carl Zeiss Microscopy,Thornwood, NY) at 60x magnification to visualize 
the physical puncture by nanoneedles and associated molecular uptake. Images were 




3.2.4 Centrifuge loading 
3.2.4.1 Sample preparation 
Tubes for centrifuge loading were made out of 1.5 ml microcentrifuge tubes 
(Eppendorf, Hauppauge, NY), modified to hold nanoneedle arrays at the bottom of the 
tube parallel to the bottom surface. A poly(methylmethacrylate) (PMMA; McMaster-
Carr, Atlanta, GA) sheet with a thickness of approximately 5 mm was cut by CO2 laser 
(Universal Laser systems, Scottsdale, AZ) into a T shape. Poly(dimethylsiloxane) 
(PDMS, Sylgard 184, Dow Corning, Midland, MI) was prepared by mixing the elastomer 
and curing agent at a ratio of 10 to 1. After degasing, the PDMS was poured into the 
microcentrifuge tube and the T-shaped piece of PMMA was placed inside the tube while 
the PDMS was curing at 37◦C. After 12 h, the PMMA was removed from the tube, 
forming a square well at the bottom of which the nanoneedle array was placed. 
DU145 cells were harvested by trypsin/EDTA (Cellgro) and re-suspended in 
RPMI. Cell concentration was measured by a Multisizer 3 Coulter Counter (Beckham 
Coulter, Fullerton, CA) and prepared for the experiment at 106 cells/ml. Cells were mixed 
with calcein (Molecular Probes, Eugene, OR), 20 kDa FITC-labeled dextran (Sigma-
Aldrich, St. Louis, MO), and FITC-labeled BSA (Sigma-Aldrich) to a final concentration 
of 10 µM to serve as markers of intracellular uptake.  
3.2.4.2 Delivery method 
 In each custom-made microcentrifuge tube, a nanoneedle array was placed on the 
bottom surface of the well with the nanoneedles facing up and 300 µl of a solution 
containing cells and a fluorescent dye was added to the microcentrifuge tube. The tubes 
were spun at varying centrifugal force and time using one of two swing-bucket 
centrifuges, Centrifuge 5702RH (Eppendorf) and Sorvall Legend RT+ centrifuge 
(Thermo Scientific, Waltham, MA).  
Fifteen minutes after the spin, cells were transferred to unmodified 1.5 ml 
microcentrifuge tubes by pipetting with RPMI to detach cells off the nanoneedles. To 
remove extracellular fluorescent molecules in the medium and on the surface of the cell 
membrane, cells were washed three times with PBS (Cellgro) at 300 x g for 5 min. After 
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the third wash, the cells were resuspended in PBS and transferred to flow cytometry tubes 
for analysis. Propidium iodide (PI, Invitrogen, Grand Island, NY) was added at a final 
concentration of 5 µg/ml 10 min before flow cytometry analysis to stain non-viable cells 
and thereby measure cell viability. 
3.2.4.3 Analysis and quantification 
The uptake of fluorescent dyes and cell viability were measured using a bench-top 
flow cytometer (BD LSRII, BD Biosciences, San Jose, CA) based on methods described 
previously [50, 139]. The data were collected and analyzed in FACSDiva software (BD 
Biosciences). Approximately 10,000 events were collected per sample. For cell viability, 
PI was analyzed using a PerCP-Cy5, 670 nm longpass filter for emission. The uptake of 
calcein, FITC-BSA or FITC-dextran was measured by a FITC, 530/30 nm bandpass filter 
for emission. 
The cell gate was constructed based on forward- and side-scatter light of the 
untreated control cells. Any events within this gate were considered to be intact cells 
while any events outside the gate were considered to be cell debris or other noise. To 
determine which cells had taken up fluorescent marker compounds (i.e., calcein, BSA 
and dextran for uptake; PI for viability), histogram gates were set by the sham control 
which had fluorescent dyes in the solution but was not treated with nanoneedles to 
account for extracellular staining and other noise. To set gates and account for possible 
spectral overlap between the dyes, compensation controls were prepared and tested. The 
positive control was prepared by staining cells with calcein AM (Invitrogen), which 
stained all viable cells. The negative control was prepared by incubating cells in 70% 
methanol for 30 min and staining with PI. 
3.2.5 Statistical analysis 
A minimum of three replicates was performed for all conditions. Means and 
standard deviations were calculated from the replicates. An unpaired Student’s t-test or 
analysis of variance (ANOVA) was performed using Minitab 17 (Minitab, State College, 




3.3.1 Nanoneedle fabrication 
Nanoneedles were designed and microfabricated out of silicon to puncture 
monolayers of mammalian cells for intracellular delivery (Figure 3.3). The nanoneedles 
were spaced 10 µm apart (i.e., tip to tip), which is similar to the diameter of many 
mammalian cells in general (e.g., 4 to 25 µm [144]) and of the DU145 cells used in this 
study specifically (i.e., 15 – 20 µm), so as to direct at least one nanoneedle per cell in a 
confluent monolayer (Figure 3.3.a). The height of each nanoneedle was 12 µm, which is 
again similar to the cell diameter so that the nanoneedles can puncture deeply into the cell 
and overcome possible cell membrane deformation during puncture. More specifically, 
the nanoneedles were designed to have a base pedestal of 6 µm height and approximately 
3 µm width topped with a 6 µm tall pyramidal portion tapering to a 23 nm sharp tip 
(Figure 3.3.b). A tip diameter below 100 nm was desirable in order to achieve the high 
cell viability shown in previous studies of single-needle intracellular delivery [87, 88, 
145]. The nanoneedles were etched on silicon wafers, which were diced to 5 mm x 5 mm 
chips, which contained approximately 250,000 nanoneedles per chip.  
 
 
Figure 3.3. Scanning electron microscopy images of nanoneedles. (a) Section of an 




We also made two variations on the nanoneedle design: nanoneedle tips and 
nanoblades (Figure 3.4). The nanoneedles tips were fabricated as the tapered pyramidal 
tips of the nanoneedles without the base pedestals (Figure 3.4. a). The nanoneedle tips 
had a height of approximately 3 µm and tip diameter of 20 – 30 nm. The nanoblades were 
fabricated with the same geometry as the nanoneedles, except with a wider tip in one 
dimension (Figure 3.4.b). The height of the nanoblades was the same as the nanoneedles, 
but the tip width and thickness were 1 µm and 25 nm, respectively. Although the 
nanoblade tips were bigger than the sharp-tipped nanoneedles, they were still smaller 
than the glass pipettes commonly used for microinjection, which often have an outer 
diameter of approximately 0.5 - 1 µm [134]. Chips containing the nanoneedle tips or the 




Figure 3.4. Scanning electron microscopy images of (a) nanoneedle tips and (b) 
nanoblades.  
 
3.3.2 Puncture loading of adherent cells 
Nanoneedles were used to puncture monolayers of adherent cells and thereby 
enable intracellular delivery of molecules. DU-145 human prostate cancer cells were 
cultured on a petri dish as a confluent monolayer and nanoneedles were brought down 
onto the cells to puncture them. Nanoneedle movement was controlled along the z-axis 
(i.e., vertical movement) by a force gauge mounted on a motorized test stand. The 
position on x or y-axis was fixed.  
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As a first assessment of intracellular delivery using nanoneedles, nanoneedle 
arrays were applied to cells incubated in a solution of calcein (used as a marker of 
intracellular uptake) using a puncture force of 0.1 N and left in contact with the cells for 2 
min. The nanoneedles were brought down upon the cells at an application speed of 150 
mm/min and back up from the cells at a retraction speed of 10 mm/min. The retraction 
speed was slow in order to reduce the chances of cells being pulled off the petri dish 
during retraction. These speeds are in the range of speeds used for insertion of 
micropipettes during conventional microinjection [146, 147].  
After nanoneedle puncture, we imaged the cell monolayers using fluorescence 
microscopy to assess cell detachment from the petri dish, intracellular uptake of calcein 
and cell viability measured by staining with propidium iodide (Figure 3.5). The 
brightfield images were used primarily to assess possible detachment of cells from the 
petri dish after nanoneedle treatment (Figure 3.5.a). At the conditions used, there was 
only minor detachment observed (i.e., < 10% of cells).  In contrast, more significant 
detachment was observed when greater contact was made with the cells using blunt 
nanoneedle base pedastals (without the tapered pyramidal tips) and using bare silicon 
without nanoneedle structures (data not shown). Altogether, these findings suggest that 
adhesion between cells and nanoneedles can lead to cell detachment, but that sharp-
tipped nanoneedles and slow retraction minimize this effect.   
The green fluorescence images indicate the extent of intracellular uptake of 
calcein, which occurred extensively in the area treated by the nanoneedle array, which is 
clearly evident as a square of green fluorescence (Figure 3.5.b). The surrounding non-
fluorescent cells serve as an internal negative control of cells that were exposed to calcein 
and subjected to the same procedures as the other cells, except they were not contacted 
with nanoneedles.  
Cells that were non-viable after the nanoneedle treatment were marked by the red 
fluorescence of propidium iodide (Figure 3.5.c). This analysis shows that some of the 
cells were rendered non-viable by the process, but that most of the cells remained viable. 
To supplement this propidium iodide assay, cells were cultured for 24 h after nanoneedle 
puncture and viability was assessed relative to untreated controls (Figure 3.6). In the 
untreated controls, the percentage of intact cells and viable cells were statistically same at 
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both time points (Student’s t-test, p = 0.258 and 0.163 for 0 and 24 h, respectively). 
When the cells were treated with the nanoneedles, the detachment of cells from the 
surface was observed initially but was not significant compared to the untreated control 
(Student’s t-test, p = 0.062). Due to the membrane puncture by nanoneedles, the viability 
decreased slightly (Student’s t-test, p = 0.018) but most of the cells remained viable at an 
applied force of 0.1 N. After 24 h incubation, the percentage of intact cells were 
comparable to the percentage of viable cells at 0 h (Student’s t-test, p = 0.995) and the 
majority of the cells were also viable (Student’s t-test, p = 0.568). The ratio of intact cells 
in treated sample to untreated control was 0.782 and 0.604 at t = 0 and 24 h, respectively, 
and the difference was not significant (Student’s t-test, p = 0.3012). The ratio of viable 
cells in treated sample to untreated control was 0.679 and 0.564 at t = 0 and 24 h, 
respectively, and the difference was also not significant (Student’s t-test, p = 0.6296). 
Thus, there was a good correlation between viability measured by the propidium iodide 
assay shortly after nanoneedle puncture and viability determined after 24 h. 
This qualitative analysis demonstrates that application of nanoneedles to cells can 
deliver molecules into the cells while maintaining cell viability. Quantitative measures of 
uptake and viability are presented further below.  
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Figure 3.5. Representative fluorescence microscopy imaging of cell monolayers after 
puncture with nanoneedles. Brightfield (a), green fluorescence (b), and red 
fluorescence (c) images of DU145 cells are shown after puncture loading using 
nanoneedles applied with a force of 0.1 N for 2 min. Green fluorescence indicates the 
intracellular uptake of calcein. Red fluorescence indicates propidium iodide 




Figure 3.6. The percentage of intact (gray) and viable (white) cells at 0 and 24 h with 
and without the puncture loading. Control cells were untreated. Treated cells were 
punctured with nanoneedles at the applied force of 0.1 N for 2 min. Data show 
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3.3.2.1 Imaging of cells during puncture loading 
This research is based on the hypothesis that nanoneedles puncture cells and 
thereby permit entry of molecules into the cells. To further test this hypothesis, we 
imaged cells by confocal microscopy during puncture by nanoneedles (Figure 3.7). The 
cells were stained with Hoechst dye to stain the nucleus blue and CellMask Orange to 
stain the cell membrane red. In untreated cells, the blue nuclei can be seen surrounded by 
red cell membranes (Figure 3.7.a). Cells punctured by nanoneedles (i.e., with the 
nanoneedles still in place) similarly show blue nuclei and red cell membranes, but also 
display a regular array of black dots (Figure 3.7. b and c). Because the spacing of these 
black dots is approximately 10 µm and the size of each black dot is approximately 0.5 
µm, we interpret these black dots as representing the presence of nanoneedles (which do 
not fluoresce green or red). There were typically a few nanoneedles associated with each 
cell, since the cell diameter was 15 – 20 µm when spread on the culture dish. Images of 
x-z and y-z planes (Figure 3.7.d and e) show cell deformation associated with the 
nanoneedles during their apparent puncture into the cells by shape of the needle tips on z-









Figure 3.7. Imaging of a monolayer of cells punctured by an array of nanoneedles by 
confocal microscopy (z-stack). (a) Untreated cells. (b) Cells punctured by 
nanoneedles, with nanoneedles still in place. Cells were stained with Hoechst (blue) 
and CellMask orange (red) to label the nucleus and cell membrane, respectively. 
Red, green, and blue lines in (b) indicate the positions on x, y, and z-axes, 
respectively. The white dotted line box in (b) is magnified in (c) at higher resolution. 
The white circles in (b) and (c) show the array of nanoneedle punctures. (d) and (e) 
show the x-z and y-z plane images, respectively, for the corresponding puncture site 
shown by white circles in (c). Scale bars (white in (a), (b), and (c) and black in (d) 
and (e)) are 5 µm. 
 
We performed additional imaging with using cells loaded with an intracellular 
marker, calcein AM, to observe molecular transport associated with the puncture loading 
method. The cells were loaded with calcein AM prior to the puncture and stained with 
Hoechst and CellMask Orange, as above. Successful nanoneedle puncture of the cells 
would therefore be indicated by loss of green intracellular fluorescence due to transport 
of calcein out of the cell. In this study, the cells were imaged a few minutes after 
puncture loading was initiated with the nanoneedles still in place (Figure 3.8).  
In untreated control cells, the imaging shows cells with blue nuclei and red cell 
membranes filled with green calcein surrounded by a dark extracellular space (Figure 
3.8.a). In cells punctured with nanoneedles, the blue nuclei and red cell membranes are 
again evident (Figure 3.8.b). However, the calcein molecule leaked out of the cell as the 
cell membrane was permeabilized by the nanoneedles. The intracellular and extracellular 
calcein concentration equilibrated and resulted in similar level of green fluorescence 
inside and outside of the cell. The presence of nanoneedles is also seen as a regular array 
of black dots with a spacing of 10 m. The nanoneedles are clearly seen due to good 
contrast with the green color.  
We conducted additional experiments with calcein in the extracellular 
environment instead of preloading cells with calcein AM. These uptake experiments 
showed similar results, with dark cells in the absence of nanoneedle puncture and green 
cells with nanoneedle puncture (data not shown), consistent with the fluorescence 
microscopy images above. To better understand the kinetics of transport, cells were 
punctured with nanoneedles in the presence of calcein and then the calcein solution was 
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replaced with fresh cell media 1 min after nanoneedle puncture, but before the 
nanoneedles were removed. In this case, there was similarly good uptake (data not 
shown), indicating that most transport happens with a min after nanoneedle puncture.  
To further investigate transport kinetics, we punctured the cells with nanoneedles 
in the absence of calcein for 2 min, and then added calcein within 1 s or 1 min after the 
nanoneedles were removed and found that intracellular uptake was minimal (data not 
shown).  These findings suggest that intracellular uptake occurs at the time of nanoneedle 
puncture and/or shortly thereafter and does not significantly occur after nanoneedle 
removal. Previous studies employing other methods of intracellular delivery associated 
with physical breaches of the cell membrane have reported cell membrane resealing times 
on the order of 1 to 100 s after electroporation [148], 10 – 30 s after puncture with a 
microinjection [149] and 1 min or more after exposure to acoustic cavitation [55]. The 
relatively rapid cell membrane resealing time observed here, apparently within seconds 
after nanoneedle removal, could be explained by the extremely sharp nanoneedle tips 




Figure 3.8. Imaging of a monolayer of DU145 cells pre-loaded with calcein AM and 
punctured by an array of nanoneedles by confocal microscopy. (a) Untreated cells. 
(b) Cells punctured by nanoneedles, with nanoneedles still in place. Each image is 
shown with (i) three channels merged, (ii) only the FITC channel for calcein AM, (c) 
only the Hoechst channel for the nucleus stain and (d) only the TRITC channel for 
the cell membrane stain (CellMask Orange). An array of black dots, with 
approximately 10 µm in spacing, is visible especially in FITC channel showing the 
tips of the nanoneedles. Green fluorescence in the extracellular space and lack of 
green fluorescence intracellularly in image (b) indicate that the calcein molecules 




3.3.2.2 Effect of molecular weight of uptake marker on uptake and viability 
Building off the initial evidence for intracellular delivery of calcein and 
nanoneedle puncture into cells, we next studied the effect of molecular weight on 
delivery efficiency by measuring uptake of three different fluorescent molecules (Figure 
3.9). Fluorescence microscopy shows that all of the fluorescent molecules were delivered 
into cells in the treated area, marked by the dotted line (Figure 3.9.a). Quantitative 
analysis of these images shows that intracellular uptake decreased with increasing 
molecular weight (ANOVA, p = 0.027), ranging from ~50% delivery efficiency for 
calcein (i.e., 50% of cells contained calcein) to ~20% delivery efficiency for the dextrans 
(Figure 3.9.b). The delivery efficiency of calcein (623 Da) was significantly higher than 
either of the dextrans (Student’s t-test, p = 0.035 and 0.025 for 70 kDa and 500 kDa 
dextran, respectively), but there was no significant difference in delivery efficiency 
between the two dextrans despite a difference in molecular weight of almost an order of 
magnitude (Student’s t-test, p = 0.97). Since the puncture condition was same in each 
case, the viability was ~90% for all three molecules (ANOVA, p = 0.56).  
We also conducted a preliminary study on intracellular delivery of other 
macromolecule using the same puncture conditions. Plasmid DNA encoding for green 
fluorescent protein (GFP) was also delivered to cells, but only low levels of transfection 
(i.e., < 5%) were observed 24 h post-treatment (Figure 3.10). We conclude that molecules 
over a range of different sizes can be delivered into cells using nanoneedles, but delivery 
of low molecular weight compounds appears to be more efficient that macromolecules.  
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Figure 3.9.  Effect of molecular weight on intracellular uptake and viability of 
DU145 cells after nanoneedle puncture. Puncture for was 0.1 N, puncture time was 2 
min and the down and up speeds were 150 and 10 mm/min, respectively. (a) 
Representative green fluorescence images show cells with intracellular uptake of (i) 
calcein, (ii) 70 kDa FITC-dextran and (iii) 500 kDa FITC-dextran. Representative 
red fluorescence images show the corresponding non-viable cells (iv, v, vi). Dotted 
lines indicate the area treated with nanoneedles. Scale bars are 1 mm. (b) 
Quantitative data on delivery efficiency and viability were generated from image 

























Figure 3.10. Green fluorescence images showing the transfection of plasmid DNA 
encoding for green fluorescent protein in DU145 cells 24 h-post puncture with a 
applied force of 0.1 N for 2 min. Scale bars (white) are 50 µm. 
 
3.3.2.3 Effects of puncture force and time on intracellular uptake and viability 
We next examined the effect of puncture force on cell viability and delivery 
efficiency of 70 kDa FITC-dextran while maintaining a fixed puncture time of 120 s 
(Figure 3.11). Fluorescence microscopy shows that all of the conditions tested were 
effective in delivering the fluorescent dextran molecule to many cells, while also killing 
some of the cells in the treated area marked by the dotted line (Figure 3.6.a). Quantitative 
analysis of the images shows that intracellular uptake of the dextran molecule increased 
(ANOVA, p = 0.022) and cell viability decreased (ANOVA, p = 0.027) with increasing 
puncture force. At 0.1 N puncture force, viability was ~90% but delivery efficiency was 
only about 20%. At 0.5 N, most of the viable cells (~50%) showed uptake of dextran. We 
conclude that greater puncture force can increase intracellular uptake, but there is a trade-





Figure 3.11. Effect of nanoneedle puncture force on intracellular uptake and 
viability of DU145 cells. Puncture time was 2 min and the down and up speeds were 
150 and 10 mm/min, respectively. (a) Representative green fluorescence images 
show cells with intracellular uptake of 70 kDa FITC-dextran after puncture at 0.1 N 
(i), 0.3 N (ii) and 0.5 N (iii). Representative red fluorescence images show the 
corresponding non-viable cells (iv, v, vi). Dotted lines indicate the area treated with 
nanoneedles. Scale bars are 1 mm. (b) Quantitative data on delivery efficiency and 
viability were generated from image analysis of the micrographs in (a). Data show 
























We next quantified intracellular uptake and viability at varied puncture times 
while maintaining a constant puncture force of 0.5 N (Figure 3.12). There was a small 
increase in delivery efficiency with longer puncture time, but it was not statistically 
significant (ANOVA, p = 0.66). The viability decreased significantly with longer 
puncture time (ANOVA, p = 0.016), from ~90% after 1 s puncture time to just ~50% 
after 120 s puncture time. These data suggest that longer puncture times compromise 
viability with little benefit to delivery efficiency. It appears that the initial force of 
puncture may be the more important factor in the uptake process.  
 
  
Figure 3.12. Effect of nanoneedle puncture time on intracellular uptake and 
viability of DU145 cells. Puncture for was 0.5 N and the down and up speeds were 
150 and 10 mm/min, respectively. Data were generated from image analysis of 
fluorescence micrographs of cells after nanoneedle treatment. Data show average ± 
































3.3.2.4 Cell morphological changes associate with puncture loading 
Lastly, we examined for any noticeable morphological changes that might be 
associated with the puncture loading method. Morphological changes are expected to be 
associated with the non-viable cells, i.e. apoptotic and necrotic cells. Apoptosis is a 
programmed cell death and is associated with the cell shrinkage and condensation as a 
result of protein denaturation [150, 151]. Subsequently, apoptotic bodies packed with 
cellular constituents form and degrade. Necrosis signaled by irreversible changes in the 
nucleus and in the cytoplasm and characterized by the cells swelling [152].  
The fluorescence images were analyzed to compare the area of viable and non-
viable cells after the treatment by nanoneedles array (Figure 3.13). The green and black 
cells were viable cells with and without intracellular uptake of calcein or FITC-dextran, 
respectively. And the red cells were non-viable cells that were stained with propidium 
iodide for necrotic and late apoptotic death. Non-viable cells were slightly smaller than 
the viable cells, both uptake and non-uptake, but were statistically the same (ANOVA, p 
= 0.304). In the short-term, from a few minutes to an hour post-treatment, we did not 
observe any significant difference in morphology of the cells after the treatment by the 
puncture loading method. Since the difference was minimal, it is difficult to determine 
what changes the non-viable cells are going through with the nanoneedles. Further study 
in more detail, i.e. to distinguish between apoptotic and necrotic cells, and over the long-
term may be necessary to better understand the effect of nanoneedle-mediated 




Figure 3.13. Comparison of cell size by area (arbitrary units) for any morphological 
changes associated with the puncture loading method by image analysis. From each 
image, several green (viable uptake), black (viable non-uptake), and red (non-
viable) cells were measured. Data show average ± SD, n ≥ 30. 
 
3.3.3 Puncture loading of suspension cells 
The puncture loading method was further implemented with suspension cells, 
since we have observed the successful intracellular delivery with the adherent cells. In 
order to use the method on suspension cells, it was necessary to investigate the measures 
to attach the cells firmly onto the surface with good cell viability. There are a number of 
methods available to chemically and biologically attach cells onto the surface for various 
other purposes. Among those methods, we selected a few potential candidates to try: 
poly-L-lysine, Cell-Tak, fibronectin, and retronectin. Poly-L-lysine is a cationic polymer 
[153, 154] that will enable the cells to bind to the surface due to the negative charge of 
the cell membrane [155, 156]. Cell-Tak is the commercially available protein solution 
derived from mussels and is used as a cell and tissue adhesive on a variety of substrates 
[157, 158]. Fibronectin is a glycoprotein which binds to integrins, the receptor protein on 
the cell membrane [159]. Fibronectin has been applied commonly onto microfabricated 
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recombinant fibronectin containing three functional domains to improve gene therapy 
viral transduction [162]. Successful DNA delivery via microinjection was demonstrated 
in CD34+ cells, adhered to the surface by retronectin, with high cell viability [163]. We 
tested these methods as they were widely used in many applications for attaching cells 
onto varying substrates. 
For each adhesion method, the degree of adhesion and the cell viability (i.e. 
morphology and propidium iodide staining) were observed by fluorescence microscopy 
after the treatment. Cell morphology retained the spherical shape and viability did not 
show any noticeable difference from the untreated sample (data not shown), as 
demonstrated in the previous studies for the other applications. Adhesion to the surface 
was determined by observing cell movement under the brightfield view while slightly 
tapping on the side of the petri dish. Minor movement of the cell was observed but a 
majority of the cells were immobilized to the surface (data not shown).  
We also attempted adding a centrifugation step in order to increase the possible 
area of adherence to the surface by cell spreading. Once the surface was treated with 
Cell-Tak, the cells were centrifuge onto the surface with various centrifugal forces. Cells 
were resuspended in media afterwards to determine the cell viability (Figure 3.14). At 
lower centrifugal forces, such as 500 and 1000 g-force, cell viability was similar to the 
control sample (Student’s t-test, p > 0.05). At higher centrifugal force of 3000 g-force, 
cell viability decreased from the control (Student’s t-test, p = 0.007), but was still about 
90%. From these studies, we concluded that these commercially available methods were 
effective in attaching the cells onto the surface with good cell viability as demonstrated in 




Figure 3.14. Percentage of viable cells after re-suspending K562 cells that were 
attached to the petri dish with Cell-Tak at varying centrifugal force (500, 1000, and 
3000 g-force). Data show average ± SD, n = 4. 
 
As we observed the attachment of the suspension cells onto the surface with the 
methods discussed, we moved on to apply puncture loading for intracellular delivery. 
Once the suspension cells were attached to the surface treated with retronectin, cells were 
treated with nanoneedles using the puncture condition of 0.20 N for 30 s for the 
intracellular delivery of 70 kDa FITC-dextran. Down and up speed of the force gauge 
were fixed at 150 and 10 mm/min, respectively. Cells were observed under the 
fluorescence microscope for detachment and intracellular uptake (Figure 3.15).  
In the brightfield images, the untreated area outside the nanoneedles array still 
showed good attachment of the cells. However, the excessive detachment was observed, 
especially along the edges of the nanoneedles array, while the cells were piling up in the 
center of the treated area as seen in each close-up image. The cell detachment and 
migration to the center of the area was possibly due to the surface tension and/or 
convective motion of the liquid when the nanoneedles were lifted after the puncture. The 
delivery efficiency of dextran molecule was very low compared to the puncture loading 
on the adherent cells. The cells were not as firmly attached to the surface as adherent 
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between nanoneedles instead of puncture at the tip. We concluded that intracellular 
delivery into suspension cells would be difficult unless there is a better method of cell 
immobilization due to cell detachment and migration with the nanoneedles movement.  
 
    
          
Figure 3.15. Brightfield images of K562 cells after puncture loading showing severe 
detachment along the edges and cell concentration at the center of the treated area. 
Top left image shows the entire area treated by the nanoneedles array. Dark blue 
lines indicate where the close-up views (1, 2, and 3) are. Red lines show where the 
edges of the nanoneedles array were. Scale bars are 1 mm (top left) and 500 µm (1, 
2, and 3). 
 
We further tested the immobilization of suspension cells on microfabricated 
surfaces, in collaboration with the laboratory of Wilbur Lam (Georgia Tech). The surface 
was patterned with square and circular wells, a few micrometers in depth, for the 




surface was treated with Cell-Tak, the cells were centrifuged at 300 g-force to promote 
attachment. Puncture loading was performed for intracellular delivery of 70 kDa FITC-
dextran using 0.2 N for 30 s. 
Cells were observed under the fluorescence microscope for detachment and 
intracellular uptake (Figure 3.16). The square and circular wells were seen in the 
brightfield view. While severe detachment was again observed, the majority of remaining 
cells were localized inside the well and showed uptake of fluorescent dextran molecules. 
Although we observed intracellular uptake of fluorescent molecules in suspension cells, 
we concluded that the immobilization techniques were not strong enough and not suitable 




Figure 3.16. Brightfield and green fluorescence (intracellular uptake of 70 kDa 
FITC-dextran) images of K562 cells after the puncture loading on fabricated 
polystyrene surfaces (Lam lab). Scale bars are 100 µm. 
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3.3.4 Centrifuge loading 
As an alternative approach to the method of puncture loading by bringing 
nanoneedles to a monolayer of cells, we developed a second method of centrifuge loading 
achieved by spinning cells down onto a nanoneedle array, which was fixed at the base of 
a centrifuge tube,. We hypothesized that the centrifugal force could bring the cells to the 
needles and result in impalement to promote uptake of molecules.  
3.3.4.1 Effect of centrifugal force and time on intracellular uptake and viability 
To test the feasibility of the centrifuge loading method, several centrifugation 
conditions were tested. We first quantified the uptake of calcein and the viability of 
DU145 cells over a broad range of centrifugal forces using all three types of nanoneedles:  
nanoneedles, nanoneedle tips and nanoblades (Figure 3.17). Centrifugal force was varied 
from 65 to 10000 g-force, while the centrifugation time was fixed at 2 min. At low 
centrifugal forces, 65 and 500 g-force, the viability of the cells treated with nanoneedles 
and nanoneedle tips were statistically same compared to the control (ANOVA, p = 0.487 
and 0.200 for nanoneedles and nanoneedle tips, respectively). As the centrifugal force 
increased to 5000 and 10000 g-force, the decrease in viability was observed (ANOVA, p 
= 0.000). The increase in centrifugal force could have resulted in more cells sticking to 
the array and/or cell fragmentation. For all centrifugation conditions, the viability of the 
cells treated with nanoblades decreased significantly from the control and compared to 
the cells treated by other needle types (ANOVA, p = 0.000), which could be due to the 
bigger tip size of the nanoblades.  
The delivery efficiency of calcein ranged between 10% and 50% of the cells 
collected after the centrifuge loading (Figure 3.17). We initially expected that as the 
centrifugal force increased, the delivery efficiency of calcein would increase as well due 
to stronger force to bring cells to the needles and puncture the cell membrane. Instead, we 
observed relatively high delivery efficiency at low centrifugal forces of 65 and 500 g-
force and decreased uptake efficiency with higher centrifugal force (ANOVA, p < 0.001).  
Among the three needle types tested, we predicted the nanoblades to make bigger holes 
in the cell membrane, which would result in better uptake of molecules. However, the 
percentage of cells with calcein uptake after treatment with nanoblades was 
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approximately 10 – 15%, which was always lower than in the nanoneedle and nanoneedle 
tip samples (ANOVA, p < 0.04). Nanoneedles performed slightly better than nanoneedle 
tips at 65 and 500 g-force (Student’s t-test, p < 0.05) and equivalently at 5000 g-force 
(Student’s t-test, p = 0.33). For both nanoneedles and nanoneedle tips, the delivery 
efficiency did not vary significantly between 65 and 500 g-force (Student’s t-test, p > 
0.2). Based on these results, the optimal centrifuge condition was with nanoneedles or 
nanoneedle tips at 65 or 500 g-force.  
 
 
Figure 3.17. Effect of centrifugal force on the intracellular uptake of calcein and 
viability of DU145 cells. Centrifugation time was fixed at 2 min. Cells were treated 
with nanoneedles, nanoneedle tips, or nanoblades. Data were generated by flow 
cytometric analysis. Asterisk (*) indicate the conditions with no data available. Hash 
symbol (#) shows data where viability was lower than the untreated calcein control 
(Student’s t-test, p < 0.05). Data show average ± SD, n ≥ 3.  
 
We next assessed the effect of centrifugation time on delivery efficiency and 
viability. Using a low centrifugal force of 0.65 g-force (100 rpm), the delivery efficiency 
of calcein and cell viability were quantified after centrifugation times of 5 min and 20 
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cells collected after treatment was above 90% and did not differ significantly from the 
control (ANOVA, p = 0.24).  
We expected the longer centrifugation time to give a greater chance for cells to 
come in contact with nanoneedles and thereby increase calcein uptake. However, for both 
nanoneedles and nanoneedle tips, the delivery efficiency of calcein was statistically the 
same at 5 min and 20 min (Student’s t-test, p > 0.1). At both centrifuge conditions, the 
nanoneedles resulted in higher calcein uptake of approximately 40% compared to about 
20% calcein uptake with the nanoneedle tips (Student’s t-test, p = 0.02), which is 
consistent with the previous data at varied centrifugal force that also showed the 
superiority of nanoneedles.  
 
 
Figure 3.18. Effect of centrifugation time on intracellular uptake of calcein and cell 
viability. Centrifugation force was fixed at 0.65 g-force (100 rpm) for centrifugation 
times of 5 min and 20 min. Cells were treated with the nanoneedles or nanoneedle 
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3.3.4.2 Effect of sample size and number of treatments on uptake and viability 
Because calcein uptake did not exceed 40 – 50% of cells at the optimal 
conditions, we hypothesized that calcein uptake could be increased further by reducing 
the number of cells per sample and by increasing the number of centrifugation treatments 
in order to increase the chances of a cell encountering, and thereby being punctured, by a 
nanoneedle. First, we reduced the number of cells per sample by reducing the cell 
concentration, guided by the estimate that spinning down approximately 125,000 cells of 
15 – 20 µm diameter would form a monolayer on a 5 mm x 5 mm nanoneedle array. We 
therefore added 62,500, 125,000, and 250,000 cells per sample in order to form 
approximately half, one, and two monolayers, respectively.  
We found that the number of cells per sample did not have a significant effect on 
viability compared to the untreated control (ANOVA, p = 0.12, Figure 3.19). Although 
we expected the percentage of cells with calcein uptake to increase with smaller sample 
size due to the increased probability of a cell encountering and thereby becoming impaled 
by a nanoneedle, the delivery efficiency of calcein was also not significantly affected by 
number of cells per sample (ANOVA, p = 0.14). Delivery efficiency was approximately 
40% in all samples. Because the percentage of cells with uptake was unaffected by the 
number of cells per sample, the absolute number of cells with intracellular delivery was 
greater in the samples with more cells. Mechanistically, however, varying the number of 
cells per sample did not provide an explanation for why uptake did not exceed 40% - 





Figure 3.19. Effect of varying number of cells per sample on intracellular uptake of 
calcein and cell viability. Cell concentration was varied to achieve different numbers 
of cells per sample guided by their ability to form a monolayer on the nanoneedle 
array after being spun down. Cells were treated with nanoneedles at 65 g-force for 2 

























We next performed an experiment to test whether increasing the number of 
centrifugation treatments would result in higher delivery efficiency of calcein. Our 
hypothesis was that by increasing the number of treatments (with mixing of the cell 
suspension between each treatment), there would be more opportunities for a cell to come 
in contact with a nanoneedle for impalement. The cells were treated at 65 g-force for 2 
minutes with both nanoneedles and nanoneedle tips using either a single centrifugation 
treatment or four centrifugation treatments.  
Contrary to our hypothesis, multiple centrifugation treatments with nanoneedles 
and nanoneedle tips did not yield significant different delivery efficiency of calcein 
compared to the single treatment (Student’s t-test, p > 0.7, Figure 3.20Figure 3.20). 
Nanoneedle tips achieved a delivery efficiency of 20 – 30% and nanoneedles performed 
slightly better, with a delivery efficiency of approximately 40%, but the data were 
statistically similar (Student’s t-test, p = 0.05). Although we were concerned that multiple 
treatments with nanoneedles might result in lower cell viability, viability levels of the 
treated samples were all statistically the same (ANOVA, p = 0.074). 
 
 
Figure 3.20. Effect of number of centrifugation treatments on intracellular uptake 
of calcein and cell viability. Cells were spun down either one time (single) or four 
times (multiple) at 65 g-force for 2 min with nanoneedles or nanoneedle tips. Data 





















Nanoneedles                       Nanoneedle tips
 55 
3.3.4.3 Effect of reusing nanoneedles on uptake and viability 
We also assessed the feasibility of reusing the nanoneedles by comparing the 
delivery efficiency of calcein and cell viability after treatment with new nanoneedles 
versus used nanoneedles. The nanoneedles were soaked in bleach after the first 
experiment and rinsed with PBS before the second experiment.  
Intracellular uptake of calcein decreased significantly in both nanoneedles and 
nanoneedle tips when these chips were used a second time compared to the first time 
(Student’s t-test, p < 0.01, Figure 3.21Figure 3.21). As observed in previous experiments, 
the nanoneedles showed significantly higher delivery efficiency compared to the 
nanoneedle tips when use the first time (Student’s t-test, p = 0.009). However, at the 
second use, there was negligible difference in delivery efficiency between nanoneedles 
and nanoneedle tips (Student’s t-test, p = 0.11).  
Cell viability also decreased for the used nanoneedles and nanoneedle tips, falling 
to approximately 80% while the viability associated with the new nanoneedles and 
nanoneedle tips remained similar to the control sample (ANOVA, p ≤ 0.001). There was 
no difference between the viability after treatment with used nanoneedles and that after 
treatment with used nanoneedle tips (Student’s t-test, p = 0.40).  
The feasibility of using nanoneedles multiple times was investigated due to the 
time and effort put into nanoneedle fabrication. However, the performance decreased 
significantly after the first use in terms of lower viability and lower delivery efficiency of 
calcein. Nanoneedles were observed under SEM before and after the centrifuge loading 
to observe any significant difference on tips and structure of the nanoneedles (Figure 
3.22Error! Reference source not found.). SEM images of nanoneedles after the 
centrifuge loading showed that the parts of the nanoneedles were covered by cells and 
cell debris. Cleaning the nanoneedles with bleach showed the minimal difference from 
before and suggested that the dimensions of the tips could have been altered. Although 
the nanoneedles can still be used after the first time by cleaning with bleach, there may be 
a decrease in the viability and delivery efficiency, possibly due to dull of damaged 






Figure 3.21. Effect of reuse of nanoneedles on intracellular uptake of calcein and cell 
viability. New nanoneedles or nanoneedle tips  were used to treat cells, then cleaned 
with bleach, and then reused to treat a second cell sample by centrifugation at 500 g-
























Figure 3.22. Scanning electron microscopy (SEM) images of the nanoneedles before 
the centrifuge loading (a), after the centrifuge loading (b), and after cleaning with 
bleach (c). Scale bars (red) are 10 µm. 
 
3.3.4.4 Effects of molecular weight of uptake marker on uptake and viability 
Lastly, we tested the feasibility of using centrifuge loading to deliver 
macromolecules, which have a molecular size similar to that of many proteins and 
plasmids of interest for biological applications. We first used nanoneedles and 
nanoneedle tips to promote intracellular delivery of FITC-BSA, which has a molecular 
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weight about two orders of magnitude bigger than calcein (Figure 3.23). The delivery 
efficiency of FITC-BSA was approximately 10% using both nanoneedles and nanoneedle 
tips, and was not significantly different between the two types of nanoneedle structures 
(Student’s t-test, p = 0.13), in contrast to what we have seen with intracellular delivery of 
calcein. As we saw with puncture loading, the delivery efficiency of macromolecules was 
less than for small molecules, but this difference was more pronounced during centrifuge 
loading, which could mean the holes created by the nanoneedles were smaller and/or 
shorter-lived during centrifuge loading than puncture loading. As observed previously, 
the viability levels of the cells treated with FITC-BSA were not significantly different 
from the control sample (ANOVA, p = 0.22).   
 
 
Figure 3.23. Intracellular uptake of FITC-BSA and cell viability. Cells were treated 
with centrifugation at 65 g-force for 2 min using nanoneedles and nanoneedle tips. 
Data show average ± SD, n = 5. 
 
We also attempted the intracellular delivery of pGFP by collecting cells after 
treatment with centrifugation at 65 g-force for 2 min and quantifying the transfection 
efficiency 24 h post-treatment. Unfortunately, pGFP transfection efficiency was only 
about 1% at the tested condition (data not shown). This result further suggests that the 
delivery of macromolecules (i.e. proteins and plasmids) is difficult with the centrifuge 























This study developed nanoneedle-mediated intracellular delivery methods to 
deliver molecules directly into cells using a high-throughput issue approach. Toward this 
goal, we fabricated arrays of nanoneedles and studied their effect on intracellular delivery 
and cell viability at a variety of different experimental conditions using two different 
methods: puncture loading and centrifuge loading. These studies showed delivery of 
molecules into up to half of the treated cells with no significant loss of cell viability.  
Intracellular delivery of molecules while maintaining high cell viability is of 
widespread interest. While single-cell microinjection is the gold standard for reliable 
delivery, it has extremely slow throughput [73, 74]. Viral delivery methods can have high 
efficiency, but are limited to DNA and RNA delivery and are associated with safety 
concerns [24, 40]. Chemical delivery methods, such as cationic lipids and polymers, can 
also be efficient, but utilize the endocytic uptake pathway that can degrade delivered 
molecules and reduce efficiency, and can also be limited by cell toxicity [45]. Physical 
methods, including electroporation, ultrasound and microfluidics, allow direct access to 
the cell cytosol avoiding endocytosis, but often have trade-offs between achieving high 
uptake levels and maintaining high cell viability [50, 164].  
We sought to mimic the reliability of delivery associated with microinjection by 
using a similar approach of physically by-passing the cell membrane by directly 
puncturing with a microscopic needle. We also sought to overcome the main limitation of 
microinjection (i.e., very low throughput on the order of 102 cells per hour) by fabricating 
chips containing on the order of 105 nanoneedles for treatment of 104 to 105 cells at a 
time. Our approach differed, however, from conventional microinjection in that our 
needles were solid and served to create holes through with molecules could diffuse, 
whereas microinjection typically involves hollow microneedles through which molecules 
are delivered by convective flow into the cell.  
There have been studies to accelerate the rate of microinjection using automation 
of the microinjection system for rapid sequential cell treatment [165, 166]. However, 
there are difficulties in using the automated microinjection system for large numbers of 
cells, especially for adherent cells. Reliability, repeatability, and accuracy of the method 
need further improvement and the system requires some amount of manual work [167]. 
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This serial approach of rapidly puncturing one cell at a time by microinjection is still 
much slower than then the parallel approach using nanoneedles that treats thousands of 
cells simultaneously.  
Other physical methods of intracellular delivery require significant optimization 
based the cell type used. For example, electroporation parameters, such as buffers, pulse 
voltage and pulse duration, need to be optimized for each cell type in order to achieve 
successful delivery with high cell viability [1, 5]. Ultrasound and microfluidic methods 
likewise require optimization for different cell types [8, 59] . These methods are also best 
suited for delivery to cells in suspension, although methods have been developed in some 
cases for adherent cells [168]. The nanoneedle-based approach was only studied here for 
one cell type (DU145 prostate cancer cells), but the microinjection literature suggests that 
cell puncture with nanoneedles may be broadly applicable to many cells types. In 
addition, the method can be used for both adherent cells, by puncture loading, and 
suspension cells, by centrifuge loading.  
Although the centrifuge-loading method was well suited to treat cells in 
suspension, the delivery efficiency, especially for macromolecules, was significantly 
lower compared to puncture loading. This difference could be associated with different 
biophysical properties of adherent cells, which are spread out on an immobile substrate 
during puncture loading, versus suspension cells, which are roughly spherical and have 
no supporting substrate during centrifuge loading. The associated differences in cell 
morphology, membrane elasticity and other properties [169] could lead to different 
biomechanics during cell-nanoneedle contact, such that suspension cells might be more 
easily deformed by nanoneedles, making puncture across the cell membrane more 
difficult. Suspension cells might also deform into the spaces between the rows of 
nanoneedles during centrifuge loading, thereby avoiding puncture.  
Intracellular delivery using nanoneedles is believed to depend on diffusion of 
molecules into cells through pores in the cell membrane. For this reason, delivery 
efficiency should depend on the pore size, the lifetime of the cell membrane pores and the 
diffusivity of the molecules being delivered. The observation that delivery of 
macromolecules was less efficient than small molecules could be explained by pore size 
on the order of 10 nm, which would allow easy access of small molecules, but hinder 
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transport of macromolecules. The small molecule used in this study, calcein (molecular 
weight of 0.6 kDa), has a radius of 0.6 nm [170]. The macromolecules are much bigger, 
where bovine serum albumin, 70 kDa dextran and 500 kDa dextran molecules have radii 
of 3.6 nm [171], 6 – 7 nm [172, 173] and 15 nm [174], respectively.  
In addition to steric hindrance of transport through pores, the effect of molecular 
weight on diffusivity could also explain the reduce uptake of macromolecules. Because 
diffusivity is inversely proportional to molecular radius [175], the diffusion of 500 kDa 
dextran is almost 25 times slower than calcein. Thus, macromolecules will be taken up 
less efficiently due to slow diffusion through transient pores in the cell membrane.  
Most previous work on intracellular delivery using nanowires or nanofiber arrays 
was achieved in a manner similar to the centrifuge loading method. Plasmid delivery 
using vertically aligned carbon nanofibers was conducted by spinning cells onto the array 
for 1 min at 600 g-force; however, an additional force was applied by manually pressing 
the arrays on the backside against PDMS after centrifugation [112]. Intracellular delivery 
was also demonstrated using CuO nanowire arrays by centrifugation with unspecified 
experimental conditions [114]. Another study achieved DNA delivery using carbon 
nanofiber arrays by manually pressing the array against a pellet of cells [176]. In other 
intracellular delivery studies, cells were simply incubated with arrays of carbon 
nanosyringes or silicon nanowires placed on the bottom of culture dishes for 12 – 72 h, 
where the gravity was used to slowly bring cells down to the nanostructures [113, 145, 
177].  
Although intracellular delivery was demonstrated in these studies, the 
experimental conditions required for cell impalement were not well characterized as in 
individual nanoneedle studies and were generally not varied to determine their effect on 
delivery efficiency and cell viability. When arrays were used in other studies, they were 
often non-uniform in the geometry and spacing between nanostructures. In this study, we 
used arrays of nanoneedles with well-defined geometry in a well-defined array and 
studied the effects of experimental parameters under controlled conditions on 
intracellular delivery and cell viability by both puncture and centrifuge loading. Using 
these data, we attempted to optimize the method for increased intracellular uptake and 
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cell viability and found conditions that had no significant loss of cell viability with up to 
~50% of cells exhibiting intracellular delivery.  
3.5 Conclusion 
This study microfabricated arrays of nanoneedles with 20 – 30 nm tips and 
assessed their effects on intracellular delivery and cell viability using puncture loading 
and centrifuge loading. Puncture loading studies demonstrated effective intracellular 
delivery of fluorescent molecules by lowering nanoneedles onto confluent monolayers of 
adherent cells. Increasing puncture force increased intracellular uptake and decreased cell 
viability over the range of conditions studied. Increasing puncture time had no significant 
effect on uptake and reduced viability. Increasing molecular weight decreased uptake and 
had no effect on viability.  
Centrifuge loading exploited the use of centrifugal force to bring cells onto the 
array of nanoneedles for impalement. Increasing centrifugal force decreased intracellular 
uptake and had no effect on cell viability over the range of conditions studied. Increasing 
centrifugation time, number of cells and number of treatments all had no significant 
effect on uptake or viability. The type of nanostructures mattered, where uptake was 
greatest when using nanoneedles, followed by nanoneedle tips and finally nanoblades, 
but viability was unchanged. The method was effective in the delivery of small 
molecules, such as calcein, but the delivery efficiency dropped significantly for 
macromolecules.  
Overall, this study developed novel methods of intracellular delivery using 
nanoneedles, identified key operating parameters and determined their effects on 
optimizing intracellular delivery and cell viability and thereby advances the field of 




EVALUATION OF THE MICROFLUIDIC DEVICE FOR THE 
EFFICIENT DELIVERY OF PROTEINS AND PLASMIDS IN THE 
TRAGET CELL LINES 
 
4.1 Introduction 
Fluid mechanical force has been studied for the permeabilization of the plasma 
membrane and delivery of macromolecules. Previous studies showed that the increase in 
shear stress caused the membrane fluidity to increase in endothelial cells [178, 179]. As a 
result, cell membrane poration was observed with the increase in membrane tension [60, 
61]. The intracellular delivery was demonstrated by microchannel devices to induce shear 
stress on cells and the diffusion on fluorescent molecules of different sizes [63]. The 
intracellular uptake and cell viability was dependent on device design, shear force and 
time applied. 
Similarly, the intracellular delivery of various molecules into different cell types 
was demonstrated using the new microfluidic device in literature [8]. The device with 
multiple constriction channels allowed the high-throughput treatment of cells by 
mechanical deformation and shear stress. In this study, we evaluated the feasibility of 
using these microfluidic devices for the efficient intracellular delivery of proteins and 
plasmids. In addition, we assessed the intracellular uptake and viability of different cells 
lines, which could be more relevant models for the future applications.  
4.2 Methods  
4.2.1 Cell culture 
 Human prostate cancer cells (DU145, American Type Culture Collection, 
Manassas, VA), human myelogenous leukemia cells (K562, American Type Culture 
Collection), and lymphoid leukemia cells (EU1, courtesy of Dr. Muxiang Zhou, Emory 
University, Atlanta, GA) were cultured in a humidified atmosphere of 95% air and 5% 
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CO2 at 37
◦C. DU145 and K562 cells were cultured with RPMI-16490 medium (Cellgro, 
Herndon, VA), which was supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum (FBS, Corning, Palo Alto, CA) and 1% penicillin/streptomycin (Cellgro) [137, 
180]. EU1 cells were cultured with DMEM medium (Cellgro, Herndon, VA), which was 
also supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Corning, 
Palo Alto, CA) and 1% penicillin/streptomycin (Cellgro) [181]. In addition to DU145 
cells, K562 and EU1 cells were used as alternative cells for the experiment based on their 
cell size and characteristics. 
4.2.2 Microfluidic loading 
4.2.2.1 Sample preparation 
  
Figure 4.1. The microfluidic device schematic [182] 
 
The silicon-based devices were fabricated to have tens of identical, parallel 
microfluidic channels. The channels have three main parameters as shown in Figure 4.1. 
The channel width and length of constriction varies from 4 – 8 µm, and 10 – 40 µm, 
respectively [8]. The devices were obtained (Courtesy of Drs. Armon Sharei, Klavs 
Jensen, and Robert Langer, MIT, Cambridge, MA and SQZ Biotechnologies, Boston, 
MA) and soaked in a 70% ethanol until used. Devices with varying constriction length, 
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width, and number were obtained and tested based on the cell size. Devices were 
assembled and completely dried prior to the experiment. 
DU145 cells were harvested by trypsin/EDTA (Cellgro) and re-suspended in 
RPMI. K562 and EU1 cells were harvested and re-suspended in RPMI and DMEM, 
respectively. Cell concentration was measured by a Multisizer 3 Coulter Counter 
(Beckham Coulter, Fullerton, CA) and prepared for the experiment at 3x106 or 10x106 
cells/ml based on the different versions of the holders used. Calcein (Molecular Probes, 
Eugene, OR) and 70 kDa FITC-labeled dextran (Sigma-Aldrich, St. Louis, MO) were 
added to cells at a final concentration of 0.2 mg/ml to serve as markers of intracellular 
uptake [8]. Allophycocyanin (APC, Sigma-Aldrich), another marker of intracellular 
uptake, was added to the cells at a final concentration of 0.05 µM due to the cytotoxicity 
associated with the marker at the concentration above 1 µM [183]. Halo TMR-tagged 
TALENs (Courtesy of Dr. William Dynan, Emory University) were added at a final 
concentration of 1.25 µM.  
4.2.2.2 Delivery method 
The volume of 100 – 150 µl of cells mixed with the desired delivery materials 
were placed in the assembled device’s inlet reservoir. The reservoir was connected to a 
compressed air line (Airgas, Atlanta, GA) controlled by a regulator (McMaster-Carr, 
Atlanta, GA) and the pressure was adjusted from 50 – 150 psi to drive the fluid through 
the device at constant pressure. The constant flow rate to drive the fluid was also tested 
by connecting the reservoir to “Genie” programmable syringe pump (Kent Scientific 
Corporation, Litchfield, CT) and using the flow rate of 100 µl/min or 1 ml/min. The 
treated cells were then collected from the other reservoir by pipet.  
Cells were incubated at room temperature for 15 minutes after the treatment for 
the cell membrane to reseal. Cells were washed three times with PBS (Cellgro) at 300 x g 
for 5 min to remove extracellular fluorescent molecules in the medium and on the surface 
of the cell membrane. After the third wash, the cells were resuspended in PBS for 
analysis. Propidium iodide (PI, Invitrogen, Grand Island, NY) or SYTOX Green nucleic 
acid stain (Invitrogen) was added at a final concentration of 5 µg/ml or 100 nM, 
respectively, 10 - 15 min before flow cytometry analysis to stain non-viable cells and 
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thereby measure cell viability. For nucleus stain, Hoechst 33342 (trihydrochloride, 
Invitrogen) was added at a final concentration of 2 µg/ml for 20 min. 
4.2.3 Analysis and Quantification 
Cell concentration was measured after the treatment to determine the cell loss due 
to clogging in the microfluidic channel and the fragmentation of cells. A volume of 50 ul 
of re-suspended cells was diluted in 10 ml of PBS, an electrolyte solution. The cell 
concentration was measured by a Coulter Counter and compared with the initial cell 
concentration to calculate the loss. 
The uptake of fluorescent dyes and cell viability were measured using a bench-top 
flow cytometer (BD LSRII, BD Biosciences, San Jose, CA). The data were collected and 
analyzed in FACSDiva software (BD). Approximately 10,000 events were collected per 
sample. For cell viability, PI and SYTOX green were analyzed using a PerCP-Cy5, 670 
nm longpass filter, and a FITC, 530/30 nm bandpass filter, respectively, for emission. 
The uptake of calcein and 70 kDa FITC-dextran was measured by a FITC, 530/30 nm 
bandpass filter for emission. The uptake of APC and Halo TMR-tagged TALENs were 
measured by an APC, 660/20 nm bandpass filter, and a PE, 575/26 nm bandpass filter, 
respectively, for emission. 
The cell gate was constructed based on forward- and side-scatter light of the 
untreated control cells. Any events within this gate were considered to be intact cells 
while any events outside the gate were considered to be cell debris or other noise. To 
determine which cells had taken up fluorescent marker compounds (i.e., calcein, dextran, 
and APC for uptake; PI and SYTOX green for viability), histogram gates were set by the 
sham control which had fluorescent dyes in the solution but was not treated to account for 
extracellular staining and other noise. To set gates and account for possible spectral 
overlap between the dyes, compensation controls were prepared and tested.  
 Cells were imaged using an inverted fluorescence microscope (Olympus IX70, 
Olympus, Center Valley, PA). Using cellSense Standard software (Olympus), images 




4.2.4 Statistical analysis 
A minimum of three replicates was performed for all conditions. Means and 
standard deviations were calculated from the replicates. An unpaired Student’s t-test or 
analysis of variance (ANOVA) was performed using Minitab 17 (Minitab, State College, 
PA). A value of p < 0.05 was interpreted as significant.   
4.3 Results 
4.3.1 Intracellular delivery to DU145 cells 
We first tested the feasibility of intracellular delivery to DU145 cells using the 
microfluidic devices with calcein and 70 kDa FITC-dextran. Cells were treated using a 
10-6 microfluidic device, where 10 is the length of the constriction in µm and 6 is the 
width of the constriction in µm. The intracellular uptake of calcein and FITC-dextran as a 
function of pressure was quantified (Figure 4.2).  
We observed the similar trend in calcein and FITC-dextran uptake as exhibited in 
previous work [8]. While the intracellular uptake of calcein was statistically similar 
(ANOVA, p = 0.209) in three pressures tested with 80 to 85% of cells exhibiting 
intracellular uptake of calcein, the delivery efficiency of FITC-dextran increased with the 
pressure from 20 to 40% of cells with uptake (ANOVA, p = 0.001). The delivery 
efficiency also depended on the size of the molecules; i.e. as the size of the molecule 
increased by about two orders of magnitude from calcein to FITC-dextran, the delivery 
efficiency was lower at each pressure tested (Student’s t-test, p < 0.05). The viability of 
the cells collected after the treatment was 96 – 98% in all conditions tested (data not 
shown) and were not statically different (ANOVA, p = 0.209).  
Based on these initial data on intracellular delivery of fluorescent molecules to 
DU145 cells, we treated the cells with plasmid DNA encoding for GFP using a 10-6 
microfluidic device at 70 and 90 psi pressure to quantify the transfection efficiency 24 h 
post-treatment. Unfortunately, pGFP transfection efficiency was only 1 – 3% in all 
conditions tested (data not shown). This result further supports the idea that uptake 
decreases with increasing molecular size, such that delivery of large plasmid DNA 




Figure 4.2. The delivery efficiency of fluorescent molecules, calcein and 70 kDa 
FITC-dextran, into DU145 cells collected after treating with a 10-6 microfluidic 
device at varying pressures of 50, 70, and 90 psi. Asterisk (*) shows statistically 
significant difference in uptake (p < 0.05). Data show average ± standard deviation 
(SD), n = 3. 
 
The previous experiments were done using a constant-pressure system. We next 
tested a constant-flow rate system with the syringe pump to avoid the possibility of 
decrease in pressure of the system due to cells clogging in the constriction channels of the 
device. In our initial experiment with the two fluorescent molecules at two flow rates, 1.0 
and 0.1 ml/min, we observed a low cell count and poor delivery efficiency of fluorescent 
molecules in flow cytometry analysis (data not shown). We counted the cells in each 
sample after treatment with 10-9 device to see the change in cell concentration (Figure 
4.3). The noticeable decrease in cell concentration after treatment in the constant-flow 
rate system was observed due to the clogging in the constriction channels and the loss of 
intact cells. Percentage of cells remaining decreased to approximately 70% and 20% for 
the flow rates of 1.0 and 0.1 ml/min, respectively (ANOVA, p < 0.001). At both flow 
rates, there was no statistically significant difference in cell concentration before and 






























constant-flow rate system was less effective, because it led to extensive loss of cells in 
the microfluidic device.  
 
 
Figure 4.3. The concentration of DU145 cells before and after washing with 
centrifuge after treatment with a 10-9 device in the constant-flow rate system. 
Asterisk (*) shows statistically significant difference in percentage of cells remaining 
(p < 0.05). Data show average ± SD, n = 3. 
   
4.3.2 Intracellular delivery to K562 cells 
We hypothesized that due to the similar sizes of DU145 and K562 cells in the 
range of 15 – 20 µm in diameter, K562 cells can be treated with the microfluidic device 
for intracellular delivery as well and result in similar delivery efficiency. However, in our 
preliminary experiments with K562 cells and fluorescent molecules, the cell counts were 
low and the delivery efficiency was low as well in flow cytometry analysis (data not 
shown). After treating cells with a 10-6 device at 70 psi, the cell concentration was 
quantified before and after washing to observe the change (Figure 4.4). There was a 
significant decrease in the percentage of cells remaining before and after washing to 70% 
and 40%, respectively, after cells were treated with the microfluidic device (ANOVA, p = 

































DU145 cells (Figure 4.3), there was a significant difference in before and after washing 
samples in K562 cells (Student’s t-test, p = 0.036). We concluded that the difference 
between before and after washing was mainly due to the treatment with the microfluidic 
device since we validated the washing step that the cells are not lost by cell counts and 
the control samples also undergo the same washing steps. 
 
 
Figure 4.4. Percentage of K562 cells remaining after treating with a 10-6 device at 
70 psi. Asterisk (*) shows statistically significant difference in percentage of cells 
remaining (p < 0.05). Data show average ± SD, n = 3. 
 
4.3.3 Intracellular delivery of proteins to EU1 cells 
As we did not see the promising result with K562 cells, we moved onto EU1 
cells, which would be similar to K562 cells since they are both leukemia cells but smaller 
in size with 7 – 15 µm in diameter. To study the intracellular delivery of protein, APC 
was chosen as a model fluorescent protein since the size of APC (104 kDa) is comparable 
to that of TALENs (110 kDa). The initial study using a 10-8 device with the APC 
concentration of 1.5 µM showed the intracellular uptake of fluorescent proteins (data not 
shown). However, in order to reduce the high extracellular fluorescence observed in the 






























concentration, the following experiments were conducted using the APC concentration of 
0.5 µM [183]. 
We quantified the delivery efficiency of APC in EU1 cells as a function of 
pressure and constriction width of the microfluidic device (Figure 4.5). We observed the 
similar trend in intracellular uptake with the change in constriction width as exhibited in 
previous work [8]. At each pressure tested, delivery efficiency increased with the 
decrease in constriction width of the device as cells undergo more deformation and are 
subject to greater shear force. The effect is more evident in the higher pressure of 120 psi 
(ANOVA, p = 0.002) compared to at 50 psi (ANOVA, p = 0.056). The data showed the 
similar trend for the effect of pressure on delivery efficiency as in DU145 cells with 
FITC-dextran. For the devices tested, the delivery efficiency was significantly different 
with pressure (ANOVA, p < 0.05) and increased by approximately four fold as pressure 
increased from 50 to 120 psi. 
 
 
Figure 4.5. The effect of pressure and constriction width of the microfluidic device 
(10-6, 10-7, and 10-8) on the delivery efficiency of APC in the EU1 cells. Data show 






































There are two ways to carry out viability analysis in our flow cytometry 
experiments. In one method, the fractions of cells detected by the flow cytometer are 
classified as viable or non-viable based on propidium iodide staining. In this method, 
cells that were lost at some point during the experiment (e.g., cells fragments into debris, 
cells remaining in the microfluidic device) are not accounted for. In the second method, 
the cells lost during the experiment are quantitatively accounted for by comparing cell 
concentration in experimental samples to cell concentration in negative control samples. 
In this second method, viability is determined on the basis of all cells treated by 
accounting for viable cells, nonviable cells and lost cells.  
In both DU145 and EU1 experiments, we observed no significant difference in 
viability of the cells treated at varying experimental conditions (ANOVA, p < 0.05) using 
the first method of analysis, where we assumed that the cell loss due to clogging in the 
constriction channels or loss to fragmented cells in washing step have not been taken into 
account. Based on this assumption, the previous measurement on the viability and 
intracellular uptake is based on only the collected cells after the treatment. We therefore 
quantified the percentage of intact EU1 cells and viable cells out of total cells we started 
with using the second method of analysis at four different conditions (Figure 4.6). 
Percentages of intact cells (i.e., cells that were not lost) were in the range of 50 – 80% 
compared to almost 100% in negative control samples. Percentages of cells remaining 
after treating at lower pressure of 90 psi were not significantly different from the control 
sample (Student’s t-test, p = 0.084 for 10-6 device, and p = 0.054 for 10-7 device), but 
were significantly smaller at higher pressure of 120 psi (Student’s t-test, p < 0.05 for both 
devices). Percentages of viable cells were all statistically smaller than the control sample 
(Student’s t-test, p < 0.05 for all experimental conditions) and were in the range of 30 – 
60%. For both devices, the significant decrease in percentage of viable cells at higher 
pressure (Student’s t-test, p < 0.05) was observed. At lower pressure of 90 psi, 
percentages of intact and viable cells were similar in both devices (Student’s t-test, p = 
0.814 and 0.826, respectively). However, with higher pressure of 120 psi, the device with 
smaller constriction width of 6 µm had significant decrease in percentage of viable cells 
(Student’s t-test, p = 0.032). Although the cell viability of the collected cells remained 
high in the previous studies, we concluded from this study that the smaller constriction 
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width of microfluidic device and the higher pressure actually resulted in decrease of the 
cell viability (i.e. intact and viable cells).  
 
Figure 4.6. The percentage of remaining/intact and viable EU1 cells after the 
treatment using 10-6 and 10-7 devices at 90 and 120 psi. Asterisk (*) and hash 
symbol (#) show statistically significant differences in percentage of remaining and 
viable cells (p < 0.05), respectively.  Data show average ± SD, n = 4. 
 
We recalculated the intracellular delivery efficiency and viability based on the 
total number of cells we started with (i.e., the second method) instead of only the cells 
that were collected after the treatment (i.e., the first method) using the obtained values of 
percentages of intact and viable cells (Figure 4.7). While we saw the statistical difference 
in intracellular delivery efficiency across the conditions we tested, the recalculated 
delivery efficiency was about 20% out of total cells in all cases and did not show 
significant difference with the change of constriction width of the device and the pressure 
(ANOVA, p > 0.05). As for the viability, all of the samples were statistically different 
from the control except for the cells treated with 10-6 device at 90 psi (Student’s t-test, p 
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test, p = 0.01). These studies demonstrated that the recalculation was necessary in order 
to determine the correct delivery efficiency and cell viability out of all cells, not just the 
collected cells. While previous studies showed that the delivery efficiency was 
significantly influenced by the width of the microfluidic device or the pressure but the 
viability was not, the vice versa was observed in the recalculated data (i.e. the 
recalculated viability decreased significantly with the smaller width of the microfluidic 
device or the pressure but the recalculated delivery efficiency was similar regardless of 
the change in the system). 
 
 
Figure 4.7. The delivery efficiency of APC and viability of EU1 cells from Figure 4.5 
recalculated based on the viability values in Figure 4.6. Asterisk (*) shows 
statistically significant differences in viability (p < 0.05), respectively. Data show 
average ± SD, n = 3. 
  
Based on our intracellular delivery result of APC to EU1 cells, we treated with 
two conditions for the intracellular delivery of halo TMR-tagged R4 TALEN. The treated 
cells were displayed on the histogram of the appropriate filter for the halo-tagged 
TALEN (Figure 4.8). Compared to the cells-only control sample, the samples with halo-
tagged TALEN added to them showed the shift in the histogram even after several 























overlapping populations were noticeable to indicate the intracellular uptake of halo-
tagged TALEN. The close overlap between two populations was likely due to the low 
concentration and the weak fluorescence of the halo-tagged TALEN used. This overlap 
made quantification of update difficult.  
 
 
Figure 4.8. PE channel histogram for Halo-tagged TALEN (R4) uptake in to EU1 
cells using two different microfluidic devices compared to control samples. Dotted 
lines indicate the upper limit on the background fluorescence signal in control cells. 
 
4.4 Discussion 
Consistent with previous studies showing that the microfluidic device can deliver 
various fluorescent and functional molecules to different cell lines [8], we also have 
demonstrated the intracellular delivery of fluorescent molecules and proteins into cells. 
Although the method works well for the delivery of fluorescent molecules and proteins, 
we saw the limitation of the method for the delivery of plasmid. We observed the low 
percentage of plasmid GFP transfection in DU145 cells. This could be possibly due to 
two factors; the size of the plasmid preventing intracellular uptake and/or the lack of 
plasmid delivery to nucleus. The size of the plasmid is a few MDa (r = 70 – 80 nm [184]) 
in general, which is about one or two order of magnitude larger than the proteins or 
fluorescent molecules we delivered (rCalcein = 0.6 nm [170], r70 kDa dextran =  6 – 7 nm [172, 
173], and rAPC = 11 nm [185]). According to the Stokes-Einstein equation, the bigger size 
Control                                                TALEN control 
10-6, 90 psi                                             10-7, 90 psi 
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of the plasmid may result in the slower diffusion to and into the cells through the 
transient pores opened on the plasma membrane. Another possibility for the low 
transfection efficiency observed could be due to the cytosolic delivery of the method. 
Plasmids need to find the correct pathway to enter the nucleus, where the site of action is, 
and may be subject to rapid degradation in cytoplasm by other organelles or cytosolic 
nucleases [186]. Based on these points, the micronfluidic method may not be suitable for 
applications requiring intracellular plasmid delivery, such as gene therapy with the 
delivery of correct donor template along with nucleases, or the delivery to nucleus.  
We experienced difficulty in using the microfluidic device for K562 cells unlike 
in DU145 or EU1 cells. Both DU145 and K562 cells show similar size measurement 
profile, with the peak of the cell diameter around 15 µm (Figure 4.9). Since the delivery 
method is based on the deformation and shear force at the constriction, we expected the 
comparable result for both cell lines due to similarity in physical characteristics, but the 
low delivery efficiency and the significant loss the K562 cell were observed after the 
treatment.  
 
Figure 4.9. The Coulter counter measurement for the cell diameter (µm) of DU145 
(left) and K562 (right) cells.  
 
We considered a few factors that may have contributed to the unpredicted result 
with K562 cells. First, the difference in membrane structure or composition of DU145 
and K562 cells can cause the difference in membrane rigidity. The decrease in plasma 
membrane fluidity is known to increase the membrane’s resistance to shear in vitro [187]. 
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The shape and membrane fluidity of different cells are determined by the composition of 
cytoskeleton, a network of complex biopolymeric molecules [188, 189]. Increase in 
resistance to shear is expected to decrease the intracellular uptake and can increase the 
chance of cells to become fragmented when force by pressure through constrictions 
instead of deforming to the constriction shape. Another possible factor for the cell loss of 
K562 cells could be the size or stiffness of the nucleus. In most types of leukemia cell 
lines, nuclei are known to be larger compared to normal leukocytes [190]. Nuclei size can 
dominate the leukemia cell deformability behavior, especially since nuclei of some cells 
are significantly stiffer than the whole cells [191-193]. We estimated the ratio of nucleus 
area to cell area (Figure 4.10) by taking fluorescence images of the cells stained for 
nucleus and plasma membrane. The nucleus:cell ratio (%) increased from 45% in DU145 
cells to 55% in K562 cells and was significantly different (Student’s t-test, p = 0.038). 
Although the change may not be substantial, there may be a threshold of the nucleus:cell 
ratio for the optimal result, high cell viability and high intracellular uptake, with the 
microfluidic device. These may suggest that the reason for low uptake and significant 
amount of K562 cell loss could be one or combination of these factors discussed. 
 
 
Figure 4.10. The nucleus:cell ratio (%) estimated by taking the cross-section images 
after staining both cell lines with Hoechst and CellMask orange plasma membrane 
stain for the nucleus and the plasma membrane, respectively. Data show average ± 





























As we observed the significant cell loss in K562 experiment and clogging in the 
microfluidic devices, we decided to look at the cell loss of EU1 after treatment and 
recalculate the uptake and viability based on the total number of cells we started with. 
Clogging in the constriction channel was observed with microscope after use and also 
visible with increase in time required to flow cells through the device, in some cases. We 
also noticed the significant number of cell loss after washing in K562 cells (Student’s t-
test, p = 0.036), which could be due to cells that were fragmented by the experiment and 
washed away after several washing steps. We concluded that the percentage of uptake 
and viability of EU1 cells were probably based on only the cells that were collected and 
intact after the treatment. While we observed the significant difference in intracellular 
uptake of fluorescent protein and high cell viability, comparable to the control, in all 
treated samples, the adjustment based on the total number of cells we started with 
changed the trend exhibited. Most of the treated sample had low viability compared to the 
control and the intracellular uptake did not vary significantly from sample to sample. This 
may be of a concern if the cells used are precious or the number of cells treated is critical 
for certain application.  
4.5 Conclusion 
This study examined the possibility of the intracellular delivery using a 
microfluidic device with constriction channels for cell deformation and shear. We have 
demonstrated the successful intracellular delivery of fluorescent molecules and proteins 
in DU145 and EU1 cells. Experimental factors, such as pressure, constriction width of the 
device, and size of the molecules, had effect on the delivery efficiency. However, we also 
identified a few drawbacks of the method that may limit the applications. Poor plasmid 
delivery and/or transfection efficiency and an incompatibility of the target cell lines may 
be considered when choosing the system. Also taking into account the cell loss in the 
device by clogging or fragmentation after treatment, the percentage of intracellular 
uptake and viability from the collected cells may not be accurate but probably have been 




NANOPARTICLE-MEDIATED INTRACELLULAR DELIVERY OF 
PROTEIN AND PLASMID 
 
5.1 Introduction 
Nanoparticles have gained interest over the years for many applications, 
especially in clinical applications of imaging, diagnosis and therapy. Nanoparticles can 
be synthesized in a number of different varieties based on the size, materials, synthesis 
methods, and shapes [117-121]. Especially in intracellular delivery, nanoparticles are 
advantageous since the small size of the particles allows the intracellular uptake by the 
endocytic pathway [194, 195]. The endocytosis kinetics depend on a number of factors, 
including materials and size [196]. In addition, different strategies allow the 
functionalization of the nanoparticle surface with a variety of ligands, based on the 
material properties, and the utilization for varying applications [197]. Therapeutic agents 
can be encapsulated into or coated on the surface of the nanoparticles for drug delivery 
across the cell membrane.  
In this study, we exploited the use of nanoparticles for intracellular delivery to 
target leukemia cells, known as hard to transfect cells. First, we screened several 
materials of the nanoparticles for cell viability and a sign of intracellular uptake based on 
an initial study with HeLa cells. Next, we assessed the intracellular delivery using the 
chosen nanoparticles to demonstrate the delivery of therapeutic agents, such as proteins 
and plasmids. 
5.2 Methods  
5.2.1 Cell culture 
Human myelogenous leukemia cells (K562, American Type Culture Collection, 
Manassas, VA), were cultured in a humidified atmosphere of 95% air and 5% CO2 at 
37◦C. K562 cells were cultured with RPMI-16490 medium (Cellgro, Herndon, VA), 
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which was supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, 
Corning, Palo Alto, CA) and 1% penicillin/streptomycin (Cellgro) [180]. 
5.2.2 Nanoparticle preparation 
Nanoparticles were prepared by first dissolving 0.5 g of 
hexadecyltrimethylammonium bromide (CTAB, Sigma-Aldrich, St. Louis, MO) in an 
aqueous solution of 70 ml of DI water, 0.8 ml of ammonium hydroxide (Sigma-Adlrich), 
and 20 ml of ethyl ether (Sigma-Adlrich), and stirring at room temperature. After 1.5 h, 
2.5 ml of tetraethyl orthosilicate (TEOS, Sigma-Aldrich) was added quickly to the 
emulsion solution for the formation of silica particles and stirred at room temperature for 
an additional 4 h. The particle suspension formed was purified by washing three times 
with DI water and two times with 100% ethanol (KOPTEC, King of Prussia, PA) by 
centrifugation at 2500 g force for 5 min (Eppendorf, Hauppauge, NY). The precipitate 
was resuspended in 20 ml of 100% ethanol and added to etching solution, composed of 
100 ml of 100% ethanol and 15 ml of hydrochloric acid (HCl, Sigma-Adlrich), to form 
mesoporous silica nanoparticles. The suspension was covered and continuously stirred at 
70 ◦C for 16 h. Then the particle suspension was purified and washed three times with 
100% ethanol and three times with DI water. The precipitate was resuspended in 20 ml of 
DI water and ultrasonicated using an ultrasonic processor VC 505 (Sonics & Materials, 
Newtown, CT) for 5 min at 25% amplification in an ice bath to prepare well-dispersed 
mesoporous silica nanoparticles. 
The concentration of the nanoparticles was measured by drying 2 µl of the 
suspension on a glass slide and measuring the changes in weight before and after drying 
on the ultra-micro-balance (SE2, Sartorius, Bohemia, NY). The size and zeta potential of 
the nanoparticles were measured by a Zetasizer Nano ZS90 (Malvern Instruments, 
Westborough, MA). 
5.2.2.1 Protein loading 
To load protein inside the pores of the mesoporous nanoparticles, varying 
concentrations of FITC-BSA (Sigma-Aldrich) or tetramethylrhodamine (TMR)-BSA 
(Invitrogen, Grand Island, NY) were prepared in 200 µl of RPMI. An equal volume of 
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nanoparticle suspension was added to the solution of fluorescent proteins. The mixture 
was well dispersed by vortexing for 30 s and was continuously shaken at 270 rpm for 1 h 
at 25 ◦C. The protein-loaded nanoparticles were separated from the supernatant, 
containing excess proteins, by centrifugation at 5900 g force for 10 min in the 
microcentrifuge 5415R (Eppendorf). The amount of fluorescent protein loaded was 
calculated by subtracting the fluorescence measured by spectrofluorometer before and 
after the loading process. 
5.2.2.2 Plasmid loading 
The nanoparticles loaded with proteins were prepared for layer-by-layer assembly 
to modify the surface charge of the nanoparticles for the plasmid coating. Nanoparticles 
were re-dispersed in 500 µl of DI water and added to 500 µl of polyelectrolyte solution, a 
solution of 0.2 M NaCl (Sigma-Aldrich) with a final concentration of poly-L-lysine 
hydrochloride (PLL, Sigma-Aldrich) of 5 mg/ml. After 15 min of coating time, the 
nanoparticle suspension was purified from the polyelectrolyte solution by centrifugation 
and washed with DI water. 
Poly-L-glutamic acid sodium salt (PGA, Sigma-Aldrich) was mixed with plasmid 
DNA at a ratio of 1:3.76 by weight for 20 min in 10 mM 4-(2-Hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, Sigma-Aldrich) buffer containing 150 mM NaCl. 
The plasmids used were Label IT Plasmid Delivery Controls, Fluorescein (Mirus Bio, 
Madison, WI) and the plasmid DNA (pDNA) encoding green fluorescent protein (GFP), 
gWIZTM-GFP (Aldevron, Fargo, ND). In a separate vial, protein-loaded nanoparticles 
were resuspended in a same HEPES buffer solution. The two solutions were mixed 
together by vortexing for 30 s, and incubated at room temperature for 30 min. The 
resulting plasmid-coated nanoparticles were purified from the polyelectrolyte/DNA 
solution by centrifugation and washed three times with DI water. The plasmid 
concentration in the supernatant was measured by a Nanodrop ND-1000 (NanoDrop 
Technologies, Wilmington, DE) to calculate the amount of plasmid adsorbed onto the 




5.2.3 Sample preparation 
K562 cells were harvested and re-suspended in RPMI. Cell concentration was 
measured by a Multisizer 3 Coulter Counter (Beckham Coulter, Fullerton, CA) and 
prepared for the experiment by plating on 24-well cell culture plates (Corning, Corning, 
NY) with a final volume of 500 µl containing 1 – 2x105 cells per sample. The 
nanoparticles loaded with protein and/or coated with plasmid were added to the cells. The 
positive controls for plasmids were prepared using Lipofectamine 200 transfection 
reagent (Invitrogen), following the manufacturers protocol.  
The cells were incubated with nanoparticles at 37◦C for 24 h to 72 h. The cells 
were washed three times with PBS (Cellgro) at 300 x g for 5 min to remove excess 
nanoparticles in the medium. After the third wash, the cells were resuspended in PBS for 
analysis. Propidium iodide (PI, Invitrogen) or SYTOX Green/Blue nucleic acid stain 
(Invitrogen) was added at a final concentration of 5 µg/ml or 100 nM, respectively, 10 - 
15 min before flow cytometry analysis to stain non-viable cells and thereby determine 
cell viability. As a general nucleus stain, Hoechst 33342 (trihydrochloride, Invitrogen) 
was added at a final concentration of 2 µg/ml for 20 min. 
5.2.4 Analysis and Quantification 
The uptake of fluorescent dyes or plasmid transfection and cell viability were 
measured using a bench-top flow cytometer (BD LSRII, BD Biosciences, San Jose, CA). 
The data were collected and analyzed in FACSDiva software (BD). Approximately 
10,000 events were collected per sample. For cell viability, PI, SYTOX green, and 
SYTOX blue were analyzed using a PerCP-Cy5, 670 nm longpass filter, a FITC, 530/30 
nm bandpass filter, and a BV473/10, 473/10 nm bandpass filter, respectively, for 
emission. The uptake of FITC-BSA, fluorescein delivery control and pGFP transfection 
were measured by a FITC, 530/30 nm bandpass filter for emission. The uptake of TMR-
BSA was measured by a PE, 575/26 nm bandpass filter for emission. 
The cell gate was constructed based on forward- and side-scatter light of the 
untreated control cells. Any events within this gate were considered to be intact cells 
while any events outside the gate were considered to be cell debris or other noise. To 
determine which cells had taken up fluorescent marker compounds (i.e., FITC-BSA, 
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TMR-BSA, and fluorescein delivery control for uptake; PI, SYTOX green, and SYTOX 
blue for viability), histogram gates were set by the sham control which had fluorescent 
dyes in the solution but was not treated in order to account for extracellular staining and 
other noise. To set gates and account for possible spectral overlap between the dyes, 
compensation controls were prepared and tested.  
Cells were imaged using an inverted fluorescence microscope (Olympus IX70, 
Olympus, Center Valley, PA). Using cellSense Standard software (Olympus), images 
were taken at 20x or 40x magnification and captured using appropriate filters.  
5.2.5 Statistical analysis 
A minimum of three replicates was performed for all conditions. Means and 
standard deviations were calculated from the replicates. An unpaired Student’s t-test or 
analysis of variance (ANOVA) was performed using Minitab 17 (Minitab, State College, 
PA). A value of p < 0.05 was interpreted as significant.   
5.3 Results 
Note: In this collaborative study, the design and fabrication of the nanoparticles 
was carried out by Dr. Hong-Wei Yang and the intracellular delivery and transfection 
experiments were carried out by Seonhee Park.  
5.3.1 Nanoparticle screening 
As nanoparticles have gained popularity over the years for application in 
intracellular delivery, we screened for suitable nanoparticles to be used for the co-
delivery of proteins and plasmids into K562 cells. Several materials of the nanoparticles 
were chosen based on the previous success with intracellular uptake in HeLa cells (Table 
5.1). The nanoparticles were prepared by adsorbing the negatively charged plasmid DNA 
encoding for GFP onto the positively charged surface of the particles. The candidates 
were screened based on the cell viability and the transfection efficiency in K562 cells 24 
h after incubation with nanoparticles. Despite the promising results with HeLa cells, most 
of results with K562 either resulted in low cell viability (< 50%) or low pGFP 
transfection efficiency (< 5%) (data not shown). There was only one exception among the 
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number of the candidates tested, which was the mesoporous silica poly-l-lysine (PLL) 
nanoparticles, which were chosen for further intracellular delivery experiments because 
of the good cell viability observed and for the feasibility of co-delivering protein and 
plasmid. 
 
Table 5.1. List of nanoparticle tested  
List of nanoparticles tested (Core + Shell) 
Core Shell 
PLGA (poly(lactic-co-glycolic) acid) PEI (Polyethylenimine) 
PLGA Chitosan 
PEO (Polyethylene oxide) Chitosan 
PAAMA (acrylic acid – maleic anhydride copolymer) Chitosan 
Silica PEI 




The scanning electron microscope (SEM) image of the mesoporous silica poly-l-
lysine (PLL) nanoparticles was obtained for visualization (Figure 5.1). The diameter of 
the nanoparticles appeared to vary but was approximately 100 nm. The size of the 
nanoparticles was suitable for intracellular uptake by endocytosis as demonstrated in the 
previous studies with gold and silica nanoparticles [198, 199]. The resolution of the SEM 




Figure 5.1. Scanning electron microscope (SEM) image of the mesoporous 
silica/PLL nanoparticles. Scale bar (red) is 100 nm. 
 
The mesoporous silica/PLL nanoparticles were prepared for intracellular delivery 
by loading fluorescent protein and plasmid as shown in the schematic (Figure 5.2, top). 
The fluorescent protein was encapsulated within the pores of nanoparticles and was 
saturated at about 0.53 µg per 1 µg of nanoparticles (Figure 5.2, bottom left). The 
plasmid was adsorbed onto the surface of nanoparticles by coating the surface with 
positively charged poly-L-lysine. For 1 µg of nanoparticles, about 0.27 µg of plasmid 
GFP could be loaded (Figure 5.2, bottom right). Once the nanoparticles were loaded with 
protein and plasmid, they were incubated with cells for intracellular delivery to observe 






Figure 5.2. Protein and plasmid loading in the mesoporous silica/poly-l-lysine (PLL) 
nanoparticles. Schematic of the loading process (top) where red, blue and green 
corresponds to rhodamine BSA, PLL and fluorescein labeled plasmid, respectively. 
The loading efficiency of protein (bottom left) and plasmid DNA (bottom right) per 
1 mg and 0.16 mg of nanoparticles, respectively. Data show average ± standard 
deviation (SD), n = 3. 
 
5.3.2 Nanoparticle mediated intracellular delivery 
The intracellular delivery was first studied in HeLa cells and examined under the 
fluorescence microscope 24 h post-incubation with nanoparticles (Figure 5.3). The red or 
green fluorescence was not observed in control samples (Figure 5.3, a and b), indicating 
that there was no intracellular uptake of naked plasmid or protein by endocytosis. 
However, the samples treated with nanoparticles (Figure 5.3, c) showed successful 
intracellular delivery of protein and plasmid as the corresponding red and green 
fluorescence was observed in the cytoplasm. Further study with nanoparticles loaded with 
rhodamine BSA and pGFP showed both the delivery of BSA and the transfection of GFP 
(data not shown). The percentage of BSA uptake was 82.55 ± 0.78% while the 
transfection efficiency was only 31.65 ± 3.89%, which was comparable to the 
transfection efficiency of about 32% by lipofectamine. The intracellular delivery of both 
protein and plasmid by nanoparticles was therefore demonstrated in HeLa cells and 




Figure 5.3. Fluorescence images showing the intracellular uptake of rhodamine BSA 
(red) and fluorescein-labeled plasmid (green) in HeLa cells. Cell nucleus was stained 
with Hoechst dye (blue). Each sample was treated with a) fluorescein-labeled 
plasmid control, b) rhodamine BSA control, and c) rhodamine BSA and fluorescein-
labeled plasmid loaded nanoparticles. The higher magnification image of the image 
in c) shows the intracellular uptake both rhodamine BSA and fluorescein-labeled 





Based on the results obtained with HeLa cells, we moved on to test the 
intracellular delivery in K562 cells. First, the delivery of both rhodamine BSA and 
fluorescein-labeled plasmid was observed with the fluorescence microscope after 24 h 
(Figure 5.4). The control samples incubated with naked fluorescein-labeled plasmid (and 
no rhodamine BSA) did not show any green fluorescence inside the cells (Figure 5.4, a). 
The positive control treated by lipofectamine with fluorescein-labeled plasmid (and no 
rhodamine BSA) showed weak green fluorescence, indicating the intracellular uptake of 
the naked plasmid (Figure 5.4, b). Both red and green fluorescence was observed in the 
cytoplasm of cells incubated with nanoparticles containing fluorescein-labeled plasmid 
and rhodamine BSA, as seen previously with HeLa cells (Figure 5.4, c).  
Once the delivery of both protein and plasmid was demonstrated, we replaced the 
fluorescein-labeled plasmid with plasmid encoding GFP to determine the transfection 
efficiency. The delivery efficiency of fluorescein protein and transfection efficiency of 
pGFP after 24 h were quantified with flow cytometry (Figure 5.5). The delivery 
efficiency of rhodamine BSA with nanoparticles was approximately 65% which was 
slightly lower than the delivery efficiency in HeLa cells. The transfection efficiency of 
pGFP was only about 2% and decreased significantly from the transfection efficiency of 
15% in lipofectamine (Student’s t-test, p = 0.000). Although nanoparticles were loaded 
with both rhodamine BSA and pGFP, the transfection efficiency dropped significantly 
from the delivery efficiency (Student’s t-test, p = 0.000). In K562 cells, the delivery 
efficiency or transfection efficiency was lower than HeLa cells, but co-delivery of protein 





Figure 5.4. Fluorescence images showing the intracellular uptake of rhodamine BSA 
(red) and fluorescein-labeled plasmid (green) in K562 cells. Cell nucleus was stained 
with Hoechst dye (blue). Each sample was treated with a) fluorescein-labeled 
plasmid control, b) lipofectamine, and c) rhodamine BSA and fluorescein-labeled 
plasmid loaded nanoparticles. The higher magnification image of the c) shows the 
intracellular uptake both rhodamine BSA and fluorescein labeled plasmid. Scale 





Figure 5.5. The delivery efficiency of rhodamine BSA (black) and the transfection of 
plasmid GFP (white) in K562 cells 24 h after treatment with lipofectamine or 
nanoparticles. Data show average ± standard deviation (SD), n = 3. 
 
5.4 Discussion 
From a number of nanoparticles tested, the mesoporous silica/PLL nanoparticles 
showed the most promising result on the intracellular delivery of protein and plasmid in 
both HeLa and K562 cells. Although nanoparticles were successfully used for the 
intracellular delivery in HeLa cells, the viability or the transfection efficiency was not as 
great in K562 cells. The suspension cells, especially primary and leukemia cells, were 
previously referred as “hard to transfect” cells and resulted in lower transfection 
efficiency compared to the adherent cells when commonly used transfection methods 
were used [200, 201]. This could be due to the dependence of many transfection methods 
on the cell cycle. Previous study showed that the rate of endocytosis increased with the 
increase in cell size and membrane expansion during mitosis [202]. As a result, the 
internalization of nanoparticles varied according to the different phases of cell cycle and 
was fastest at G2/M phase [203]. Similarly, the transfection efficiency of K562 cells 
using lipofectamine was found to depend heavily on the cell cycle due to change in cell 
size [204]. HeLa cells in suspension exhibited the similar behavior but the cell 






























cells were found to have lower cell masses and to remain in a proliferation-quiescent sate 
compared to adherent monolayers [205]. Thus, the performance of nanoparticles could 
diminish significantly when used with suspension cells and may need to be optimized for 
cell viability and the intracellular uptake as the intracellular uptake depends on materials, 
size, and shape of the nanoparticles.  
Although mesoporous silica/PLL nanoparticles were loaded with both protein and 
plasmid in this study, the transfection efficiency was significantly lower than the delivery 
efficiency of protein in both HeLa and K562 cells. This could be due to several factors in 
the process. First, the plasmid degradation over time could reduce the actual amount of 
active plasmid delivered inside the cells from the initial loading amount. In previous 
study with PLGA nanoparticles, the plasmid degradation due to the acidic 
microenvironment inside the particles resulted in the lower amount of active plasmid 
released [206]. The interaction between poly-L-lysine and the plasmid could result in 
degradation of active plasmid over time. Alternatively, the release of plasmid from the 
nanoparticle could be faster than the time required for the intracellular uptake of 
nanoparticles. Using gold nanoparticles, the intracellular uptake was fully achieved 6 h 
after incubation [207]. Due to the difference in size and materials, the estimate time 
would be different but the time required for the intracellular uptake of nanoparticles 
would be still a few hours after incubation. If the plasmid is dissociated from the PLL 
coating on the surface of nanoparticles at a faster rate than the uptake, the actual delivery 
amount of plasmid could reduce from the loading amount. Lastly, the difference in the 
intracellular uptake mechanism between lipofectamine and the nanoparticles could have 
attributed to the low transfection efficiency, especially in K562 cells. The intracellular 
uptake in lipofectamine is achieved as positively charged liposomes fuse with the 
negatively charged cell membrane [208]. The nanoparticles are taken inside the cells by 
endocytosis and the rate would depend on the cell-type, size, charge, and other surface 
properties [209]. It could be possible that in K562 cells, the intracellular uptake pathway 
of nanoparticles is not as tolerated as in HeLa cells. Overall, there are many possibilities 
that could explain the lower transfection efficiency compared to the delivery efficiency of 




The intracellular delivery using nanoparticles was evaluated and demonstrated in 
HeLa and K562 cells. From the several candidates of nanoparticles, mesoporous 
silica/PLL nanoparticles were chosen due to the good viability with K562 cells and the 
possibility of delivering both protein and plasmid. Intracellular delivery to HeLa and 
K562 cells was demonstrated by preparing the nanoparticles with protein encapsulated 
inside the pores and plasmid adsorbed onto the surface. Successful delivery of protein 
and plasmid were validated by the fluorescence inside the cytoplasm. Transfection of 
plasmid GFP was also compared to the positive control by lipofectamine; in HeLa cells, 
the nanoparticles performed comparably, while in K562 cells, the transfection efficiency 
dropped significantly. Overall, the nanoparticles performed better in HeLa cells than in 
K562 cells, but demonstrated the possibility of co-delivering protein and plasmid in both 






The intracellular delivery methods have been studied for many years to efficiently 
deliver drugs across the cell membrane. Since the applications of intracellular delivery 
are widespread from research settings to clinical settings, the simple and effective 
methods need to be developed for successful results. In this study, we have developed 
and/or evaluated new intracellular delivery methods, including nanoneedle-mediated 
methods, microfluidic device, and nanoparticles, to address some of the limitations posed 
by the commercially available intracellular delivery methods. To evaluate the result and 
optimize the process, it was necessary to set few criteria based on the applications of the 
intracellular delivery. The criteria can be set for two major categories; in the laboratory 
and the clinical settings.  
In the laboratory settings, the intracellular delivery would be conducted to 
perform biochemical assays and to develop stable cell lines for in vitro studies. For these 
types of studies, it would be ideal to treat as many cells as few thousands to millions and 
be dependent on the throughput of the intracellular delivery methods to achieve the 
required sample size. For experiments that are conducted on a daily basis, the methods 
also should be simple and quick to use and the cost of the materials should not be too 
expensive per each experiment. The cell types used in these applications may not be hard 
to obtain or culture and have homogeneous cell population. Accordingly, several 
experiments can be easily conducted until the methods are optimized and having a low 
viability would be acceptable as long as the number of treated cells reach the required 
level.  
On the other hand, the examples of intracellular delivery application could be in 
the gene therapy using nanomedicines and the cellular engineering. In these applications, 
the cells types may come in a limited quantity and the efficient delivery would be 
necessary along with high cell viability to maximize the effort. The primary and 
progenitor cell types are heterogeneous and the patient to patient variability could result 
in varying viability and efficiency based on the methods. Thus, the delivery methods 
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should not require too much optimization based on the cell structure or type and the 
throughput of the method would depend on the number of cells required for each 
application, which could be still several hundreds to thousands. In addition, the 
therapeutic agents are macromolecules, such as proteins and plasmids, and may be 
available in small amounts, i.e. based on the production of engineered ZFNs, TALENs, 
and donor plasmids. The intracellular delivery methods should be designed to not waste 
the reagents and make best use of these.  
Based on these guidelines, we assessed the feasibility of using commercially 
available methods and the new intracellular delivery methods for the applications in 
research and clinical settings. Among the number of biological, chemical, and physical 
intracellular delivery methods, we focused on lipofectamine, electroporation, and 
microinjection as a standard to compare to. Lipofectamine is a chemical method and has 
been used for years due to the simplicity of the method and well developed protocol. The 
method is great for laboratory settings, especially with the adherent cells. However, the 
efficiency decreases with suspension cells and the delivery materials are limited to 
plasmid and siRNA. Lipofectamine may not be suitable for the clinical applications due 
to varying efficiency in cell types and toxicity issues.  
Electroporation is a physical method that has been used widely and studied 
extensively. Amaxa nucleofector and other commercially available equipment have 
optimized protocol for many cell types and would work well in research settings. 
However, for the cell types that are not optimized, especially for primary and progenitor 
cells, the electroporation conditions need to be optimized for cell viability and 
transfection efficiency. Once the optimized protocol is available for the desired cell type, 
the electroporation can be used for both laboratory and clinical applications since any 
macromolecules can be delivered.  
Lastly, microinjection is another physical method and is very effective due to 
direct delivering molecules intracellularly by using glass pipettes. Despite this advantage, 
the method has limited potential due to the low throughput of the method since cells are 
poked one at a time manually. Not as much optimization is required for cell variability, 
but microinjection may be difficult to use in most of the laboratory or clinical settings 
where large number of cells need to be injected.  
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Our studies on the new methods may offer advantages of the existing intracellular 
delivery methods that would be beneficial to some of the applications. In both 
nanoneedle-mediated intracellular delivery methods, the delivery of fluorescent 
molecules was observed. In puncture loading, the delivery was possible by physical 
transient hole created on cell membrane by nanoneedles, similar to microinjection, and 
the possibility of the nuclear targeting was also observed with confocal microscopy, 
which would be favorable in case of protein and plasmid delivery. Since the intracellular 
uptake is possible with the physical puncture by nanoneedles, the methods may not need 
to be optimized meticulously for each cell type. While the results were not as promising 
in the suspension cells, the treatment of adherent cells showed the delivery of 
macromolecules and can be done without detaching the cells. The array of nanoneedles 
allowed the treatment of tens of thousands cells at once. Both puncture loading and 
centrifuge loading methods are relatively simple and easy to use, except the nanoneedles 
fabrication part. Overall, nanoneedle-mediated delivery methods can be integrated with 
number of laboratory applications, where large number of cells, especially adherent, 
needs to be treated.   
The microfluidic device was effective in delivering molecules across the cell 
membrane by squeezing the cells through the constriction channels as demonstrated in 
the literature [8]. The treatment of several thousand cells at an experiment was possible 
by the tens of channels in parallel. Also the experiments can be done easy and quickly, 
within few seconds, once all the systems are set-up. The delivery of different protein 
molecules was achieved with the delivery efficiency of about 20% in EU1 cells using the 
optimized condition. Once the certain cell type can be optimized using the available chip 
designs, the microfluidic device would be useful for number of applications where the 
large number of cells need to be treated. 
Lastly, nanoparticles were studied for the intracellular delivery of protein and 
plasmid. Among number of nanoparticles we tested, mesoporous silica/PLL nanoparticles 
was chosen for further investigation. Since the throughput of the nanoparticle delivery 
method would depend on the nanoparticle concentration, the sample size can be adjusted 
easily. The plasmid transfection efficiency of HeLa cells was comparable to that of the 
positive control by lipofectamine. The results suggests that nanoparticles can perform 
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similar to commercially available method and can be more favorable for other 
applications since the co-delivery of protein and plasmid by encapsulation and coating, 
respectively, is possible.  
These intracellular delivery methods bring unique advantages in addition to 
already available methods, but there are still limitations, which can or cannot be further 
improved, as these methods are still early in the development stage. Nanoneedle-
mediated methods exhibited the limited success with the suspension cells. The suspension 
cells could not be attached firmly to the surface for the puncture loading. Centrifuge 
loading could treat the cells in suspension but the delivery of macromolecules was 
challenging. The delivery of macromolecules, especially proteins and plasmid 
transfection, will need to be further studied in both delivery methods for the extended 
application in clinical or research settings. In order to minimize the diffusion limit of the 
macromolecules and reduce the amount of reagent required, the coated nanoneedle can be 
exploited. Finally, the use of nanoneedles may be limited to once or few times, as we 
have seen in the centrifuge loading. The limited use of nanoneedles would require mass 
production in order to be widely used for different applications.  
The microfluidic device showed the intracellular uptake of protein, but the 
plasmid transfection was trivial. Due to the cytoplasmic delivery, the nuclear targeting is 
hard to achieve. Also as we have observed the low viability and lack of intracellular 
uptake with K562 cells, the device may not be feasible to use or optimize for certain cell 
lines, which could be based on the membrane or nucleus elasticity and the nucleus size. 
Similar to nanoneedles, the microfluidic device can be used for a limited number of 
times, as the clogging of the cells can cause the constriction channels to block. The 
microfluidic device could be challenging to use for the gene therapy, where delivery of 
plasmid may be necessary or target cells may be difficult to optimize with currently 
available device designs. 
The nanoparticles showed the co-delivery of protein and plasmid in HeLa and 
K562 cells but the intracellular uptake was reduced in K562 compared to HeLa cells. The 
uptake efficiency and cell viability with nanoparticles can vary with different cell types 
and may need to be optimized. The optimization could be challenging as the only 
optimization option would be the size of the nanoparticles without changing the 
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materials. In addition, the clearance of the nanoparticles after treatment could be 
problematic since the nanoparticles can accumulate in body based on the size [210, 211]. 
The accumulation of nanoparticle can have additional effect in long-term and the better 
washing technique may need to be investigated.  
Conventional and new intracellular delivery methods we studied and compared 
have been summarized in Table 6.1. Overall, we studied new intracellular delivery 
methods that can further improve the commercially available intracellular delivery 
methods in terms of delivery efficiency and possible applications. Although the novel 
intracellular delivery methods were not able to completely overcome the challenges of 
the conventional methods, these opened up new options for intracellular delivery 
applications in research and clinical settings.  
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Delivery of Throughput Advantage Disadvantage 
   Fluorescent 
molecules1  
Proteins1 Plasmid1 (cells/sample)   
Lipofectamine  Chemical HeLa 
K562 
- - pGFP 1000 – 1000000 Easy to use 
 
No protein delivery 
Possible toxicity 
Electroporation Electrical  K562 Calcein FITC-BSA pGFP 250000 – 1000000 Easy to use Requires cell-specific 
optimization 
Costly equipment 
Microinjection Needle 658D Calcein - - 1 Nuclear targeting 
Little optimization 
required 






70 kDa Dextran 
500 kDa Dextran 
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7.1 Nanoneedle-mediated intracellular delivery methods 
7.1.1 Coated nanoneedles for the intracellular delivery 
The intracellular delivery methods using nanoneedles were conducted mainly by 
mixing the fluorescent molecules in the solution before the experiment. Thus, the 
intracellular uptake process was dominated by the diffusion of the molecules through the 
transient holes on cell membrane. Instead, it would be beneficial to look into the 
possibility of coating or modifying a surface of the nanoneedles array to avoid the 
diffusion limitation and to directly deliver the molecules as in the microinjection. 
Nanoneedles array can be coated with molecules simply by dispensing small amount of 
solution and wait for the solution to evaporate as done similarly in the previous studies on 
nanofiber or nanowire arrays [112, 113]. Another possibility would be to use the surface 
chemistry to covalently bind and would be especially useful for the delivery of plasmid. 
Previously, the carodiimide-mediated condensation reaction was performed to bind 
plasmid to carbon nanofiber arrays [212]. Similarly, plasmid can bind to the silicon 
nanoneedles array by surface functionalization, i.e. making the surface hydrophobic or 
oxidation [213, 214]. 
The coating or the surface modification of the nanoneedles array would be a 
worthwhile study to observe the effect on the intracellular uptake. While these methods 
could be promising, several subsequent studies would be necessary to optimize the 
process as well. The amount of loading on nanoneedles should be optimized in order to 
not add too much thickness to the nanoneedles, which could affect the nanoneedle tip 
diameter. The loading of the molecules could not be evenly spread out through the array 
or mainly localized within the trenches, instead of the nanoneedles itself. In addition, the 
intracellular delivery methods should reflect the time required for the molecules to detach 
from the surface and enter the cell cytoplasm or the nucleus. Once the method is 
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established, the effect of the delivery efficiency, especially of macromolecules, can be 
studied by comparing with the existing experimental procedure.  
7.1.2 Imaging 
In order to understand and observe the intracellular delivery by nanoneedles in 
more details, the imaging with better spatial and temporal resolution would be essential. 
One of the possible techniques is scanning electron microscope (SEM), which utilizes the 
focused beam of electrons. Nanoneedles can be imaged after the experiments to observe 
the puncture by nanoneedles on the cell membrane. It would be also possible to 
determine the effect of various centrifuge loading parameters on the puncture depth and 
its correlation to the intracellular uptake. The SEM technique has been used for many 
decades for the imaging of samples in the nanoscale but the imaging of wet samples has 
been challenging. The samples can be imaged by either using an environmental SEM or a 
cryo-SEM technique. Environmental SEM is capable of imaging partially hydrated 
samples at low vacuum [215, 216], but obtaining the images with acceptable resolution 
and contrast may be difficult [217]. Another possibility is to prepare frozen samples by 
several dehydration steps prior to imaging [218]. The extensive sample preparation steps 
could be challenging to preserve the samples as it is without altering it. Both imaging 
techniques could make the imaging of cells after the treatment challenging, but it would 
be an interesting study to look at the interaction between cells and nanoneedles.   
Further confocal microscopy imaging would be also important to validate the 
intracellular delivery process using nanoneedles. Real-time imaging of the intracellular 
uptake would be valuable to understand the time scale of the uptake and the cell 
membrane resealing process with nanoneedles. Capturing good quality real-time images 
would depend on the temporal resolution of the system as well as designing a simple 
system that would hold the nanoneedles in place instead of continuously pushing down 
on the cells and changing the focus. Although fluorescence and confocal microscopy 
images demonstrated the intracellular uptake of fluorescent molecules, the further studies 
of the intracellular uptake process were limited by the resolution of the microscope. Due 
to the limited spatial resolution, it is difficult to view the nanoneedles at the tip, where the 
diameter is about 20 nm, but nanoneedles are only visible when the tip diameter is about 
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few hundreds of nanometers diameter. Nanoneedles can be coated with fluorescent 
molecules to possibly enhance the view and observe the interaction with the cells, instead 
relying on the presence of black holes on the fluorescence filter. Another option would be 
to try the super resolution fluorescence microscopy, where the spatial resolution was 
enhanced by almost by an order of magnitude from the confocal microscopy [219, 220].  
7.1.3 Extended application of the methods to alternative cell lines  
For the nanoneedle-mediated intracellular delivery systems to be widely used, 
several cell lines will need to be tested to validate the intracellular uptake. We 
hypothesized that the intracellular delivery would be consistent across different cell lines 
using the nanoneedle-mediated methods, since the methods do not depend as much on the 
membrane characteristics as some other methods do. Most of the intracellular delivery 
methods rely on several physical characteristics of cells and the results can vary from cell 
to cell even if the experimental conditions are consistent. A number of different cell lines 
can be chosen based on the physical characteristics and further application to test the 
nanoneedle-mediated intracellular delivery methods. Primary and stem cells are known to 
be hard to transfect with commercially available methods and widely studied for the 
application in tissue engineering and gene therapy [221]. Many progenitors cells are 
heterogeneous and can vary from patient to patient, which makes existing transfection 
methods more difficult to use [222, 223]. In embryonic and hematopoietic stem cells, the 
terminal differentiation results in stiffer cell nucleus and the irreversible deformation of 
nucleus was observed [224]. Varying stiffness of cell nucleus could affect the cell 
viability and intracellular uptake as the confocal image of puncture loading showed some 
of the nanoneedles targeting the nucleus. Lastly, the physical characteristics of the cell 
can vary with the substrate stiffness [225, 226]. By adjusting substrate stiffness, cells can 
be prepared with varying stiffness, cytoskeletal structure, and adhesion for experiments. 
It is crucial in order to extend the application for the wider use across different cell lines 





7.1.4 Cell viability and repair mechanism 
The parameters for the nanoneedle-mediated intracellular delivery methods were 
varied based on the cell viability and the intracellular uptake. The bigger size and/or 
longer opening time of pores due to applied physical force can result in the potential risk 
of cell death due to apoptosis triggered by calcium efflux or necrosis [227]. A number of 
previous studies on physical delivery methods investigated the ways to increase the cell 
viability and can be applied with nanoneedle-mediated delivery methods to improve the 
cell viability, especially with puncture loading since the effect on viability was minimal 
with centrifuge loading.  
One of the possible treatment options is adding poloxamer surfactants to protect 
the cells from shear-induced damage by increasing plasma membrane fluidity [228]. The 
increase in cell viability was observed with addition of poloxamer in several physical 
intracellular delivery methods, such as electroporation, ultrasound, and photoacoustic 
delivery [229-231]. Another treatment option is to increase the intracellular calcium 
concentration to achieve membrane recovery processes by calcium-mediated signaling 
[232]. In the micropuncture experiment on 3T3 cells, which would be similar to the 
nanoneedle-mediate methods, the membrane resealing time was delayed significantly 
with lower extracellular calcium concentration [149]. Calcium-mediated cell repair was 
also demonstrated in treatment with ultrasound and microfluidic device [233-235]. The 
effect on cell membrane resealing could be similar in nanoneedle-mediated methods 
since the size of holes would be in same order of magnitude, but since the effect could 
vary based on the cell type, cell state, and the methods, it would be interesting to observe 
how each treatment has effect on cell viability. The further study will not only be useful 
for improving the cell viability but also will provide valuable information for 
understanding the cell repair kinetics associated with the nanoneedle-mediated 






7.2 Microfluidic devices 
The newly developed microfluidic device was effective in delivering molecules to 
cytoplasm in a high-throughput manner. Based on our studies, the method was not 
suitable for the gene therapy, due to the lack of plasmid transfection observed. However, 
the preliminary result in the previous study showed the intracellular uptake of carbon 
nanotube wrapped with fluorescence labeled DNA [8]. The further work on the delivery 
of plasmid integrated with nanomaterials would be interesting in order to extend the 
application in gene therapy. By incorporating the plasmid on the nanomaterials, the 
degradation of plasmid can be delayed and the possible nuclear targeting could be 
achieved as well. The nuclear entry of gold nanoparticles could be achieved by making 
ultrasmall nanoparticles, smaller than 10 nm in size [236]. Another possible option would 
be to conjugate with nuclear localization signal (NLS) peptide, which assists the 
translocation to the nucleus, with nanoparticles [237, 238]. Although nanoparticles 
themselves can also enter the cytoplasm, the combination with the microfluidic device 
may increase the efficiency and can target cells that may have low efficiency by 
nanoparticles only.  
7.3 Nanoparticles 
The intracellular delivery of protein and plasmid by mesoporous silica/PLL 
nanoparticles was demonstrated in both HeLa and K562 cells. Both the delivery 
efficiency and transfection efficiency decreased when applied in the suspension cells. As 
this difference could be due to the cell cycle and the culture condition, the attachment of 
K562 cells on the surface prior to the experiment with nanoparticles could be a possible 
step to increase the delivery efficiency. Previously, the transfection efficiency of the 
suspension cells, using commercially available transfection reagents, improved by 
coating the surface by chicken egg white to promote the cell attachment to the culture 
plates [239]. As we have already studied several methods for the attachment of K562 
cells on the surface for the puncture loading with nanoneedles, we can easily test for the 
nanoparticle-mediated intracellular delivery. The comparison of delivery and/or 
transfection efficiency of cells cultured in suspension and on the coated plates would be 
an interesting study, accompanied by the comparison of the cell cycle for validation of 
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the hypothesis. In addition to possible increase in the delivery and transfection efficiency, 
the attachment of K562 cells on the surface would be also advantageous in washing the 
excess nanoparticles. Since the suspension cells can be washed by centrifugation, the 
majority of the excess nanoparticles forms a pellet together with cells and is difficult to 
wash. By attaching the cells on the surface, the excess nanoparticles can be easily washed 
away as done in adherent cells. Clearance of nanoparticles would make the method also 
more favorable for the clinical applications; i.e. the transplantation of treated cells back 







In this study, we examined new intracellular delivery methods in order to address 
a number of limitations posed by conventional delivery methods and to further enable 
applications in research and clinical settings. We exploited novel intracellular delivery 
methods and evaluated various experimental parameters to study the effect on 
intracellular uptake and cell viability.  
First, we demonstrated the possibility of using nanoneedles for high-throughput 
intracellular delivery. Arrays of nanoneedles with sharp tip were fabricated from silicon 
wafers to physically puncture the cell membrane for the diffusion of fluorescent 
molecules intracellularly. Two delivery methods, puncture loading and centrifuge 
loading, were developed and assessed. In puncture loading, the nanoneedles were inserted 
into the confluent monolayer of cells at varying puncture force and applied time. The 
intracellular uptake and cell viability were quantified at range of experimental parameters 
to determine the required conditions for intracellular delivery. Viability varied from 50% 
to 90% and the delivery efficiency of 70 kDa dextran ranged from 20% to 50% of cells. 
Macromolecules, up to 500 kDa, were delivered into the cells using the method. The 
method worked well for the treatment of adherent cells, but the further work may be 
necessary to attach the suspension cells with enough adhesion strength to remain in place 
during puncture loading.  
In order to treat cells in suspension, the nanoneedles were fixed and the cells were 
centrifuged onto the needles at varying centrifugal force and time in the centrifuge 
loading method. Centrifuge conditions were optimized based on the cell viability and the 
delivery efficiency of small fluorescent molecules. Cell viability was relatively high (i.e., 
> 90%) in most of the conditions tested. The optimized conditions achieved up to 60% 
delivery efficiency of small molecules, but the delivery efficiency of macromolecules 
was only approximately 10%.  
Novel microfluidic devices were studied as another physical intracellular delivery 
method to treat suspension cells in a high-throughput manner. The mechanical 
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deformation and shear stress in the constriction channels opened up transient holes in the 
cell membrane and allowed the diffusion of molecules intracellularly. Not all of the cells 
were compatible with the device, probably due to the variation in physical characteristics 
of cell membranes. Cell viability and intracellular uptake of various fluorescent 
molecules, including dextran and protein molecules, were quantified with the width of 
constriction channel or pressure tested.    
Lastly, we studied intracellular delivery using nanoparticles. From several 
materials for nanoparticles, we screened for suitable materials to achieve intracellular 
delivery in a leukemia cell line. High cell viability and intracellular uptake were seen 
with mesoporous silica/poly-L-lysine nanoparticles. Therapeutics agents could be loaded 
onto the nanoparticles either by encapsulating within the pores and/or by coating on the 
surface of the nanoparticles. Successful uptake of fluorescent protein and plasmid 






Electroporation has been used widely for transfection experiments in laboratory 
and clinical settings. Protocol have been developed and optimized for many cell types to 
result in high cell viability and high delivery or transfection efficiency. The method is 
advantageous for many cell types with already developed protocols, but electroporation 
can be challenging if the cell types used for the experiments are rare and the protocol has 
not been developed yet [5].  
We performed a series of electroporation experiments to demonstrate the 
intracellular delivery of proteins and to compare the delivery efficiency and viability with 
the other methods we studied. In addition to the optimized condition available from the 
manufacturer of the Amaxa Nucleofector II, we varied the pulse conditions with a 
CytoPulse electroporation unit to examine the effect on cell viability and intracellular 
uptake. The intracellular delivery of various fluorescent molecules, which were delivered 
in our other studies as well, was demonstrated with the optimized conditions of 
electroporation.  
A.1 Methods  
A.1.1 Cell culture 
Human myelogenous leukemia cells (K562, American Type Culture Collection), 
and lymphoid leukemia cells (EU1, courtesy of Dr. Muxiang Zhou, Emory University, 
Atlanta, GA) were cultured in a humidified atmosphere of 95% air and 5% CO2 at 37
◦C. 
K562 cells were cultured with RPMI-1640 medium (Cellgro, Herndon, VA), which was 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Corning, Palo 
Alto, CA) and 1% penicillin/streptomycin (Cellgro) [137, 180]. EU1 cells were cultured 
with DMEM medium (Cellgro, Herndon, VA), which was also supplemented with 10% 
(v/v) heat-inactivated fetal bovine serum (FBS, Corning, Palo Alto, CA) and 1% 
penicillin/streptomycin (Cellgro) [181]. 
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A.1.2 Electroporation 
A.1.2.1 Sample Preparation 
Cell concentration was measured by a Multisizer 3 Coulter Counter (Beckham 
Coulter, Fullerton, CA) and prepared for the experiment at 107 cells/ml in an 
electroporation solution. Electroporation solutions were either obtained from a 
commercially available kit (Lonza, Allendale, NJ) or made using the recipe from the 
laborator of Dr. Gang Bao’s (Georgia Tech). FITC-labeled BSA (Sigma-Aldrich), 
allophycocyanin (APC) (Sigma-Aldrich) or pGFP (Aldevron) were added to the sample 
at a final concentration of 25 µM, 0.05 – 0.1 µM, and 100 µg/ml, respectively. Halo 
TMR-tagged TALENs (Courtesy of Dr. William Dynan, Emory University) were added 
at a final concentration of 1.25 µM.  
A.1.2.2 Electroporation 
Prepared samples (100 µl) were transferred to cuvettes with an electrode spacing 
of 2 mm for electroporation. Electroporation was performed using either Amaxa 
Nucleofector II (Lonza) or CytoPulse PA-4000 (Cyto Pulse Sciences. Columbia, MD). 
Immediately after treatment, 500 µl of pre-warmed media was added to the cuvette and 
transferred carefully to either 1.5 ml microcentrifuge tubes or 12-well plates.  
The samples treated with FITC-BSA or APC were incubated for 15 min and 
washed with PBS four times at 300 x g for 5 min to remove the extracellular fluorescent 
molecules. After the last wash, the cells were resuspended in PBS and transferred to flow 
cytometry tubes for analysis. Propidium iodide (PI, Invitrogen, Grand Island, NY) was 
added at a final concentration of 5 µg/ml 10 min before flow cytometry analysis to stain 
non-viable cells. 
The samples treated for plasmid transfection were incubated for 24 h post-
electroporation.  The cells were washed once at 300 x g for 5 min and resuspended in 
PBS. Afterwards, the cells were transferred to flow cytometry tubes and PI was added to 
stain non-viable cells. 
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A.1.3 Analysis and quantification 
The uptake of fluorescent dyes and cell viability were measured using a bench-top 
flow cytometer (BD LSRII, BD Biosciences, San Jose, CA). The data were collected and 
analyzed in FACSDiva software (BD Biosciences). Approximately 10,000 events were 
collected per sample. For cell viability, PI was analyzed using a PerCP-Cy5, 670 nm 
longpass filter for emission. The uptake of FITC-BSA or transfection of pGFP was 
measured by a FITC, 530/30 nm bandpass filter for emission. The uptake of APC and 
Halo TMR-tagged TALENs were measured by an APC, 660/20 nm bandpass filter, and a 
PE, 575/26 nm bandpass filter, respectively, for emission. 
The cell gate was constructed based on forward- and side-scatter light of the 
untreated control cells. Any events within this gate were considered to be intact cells 
while any events outside the gate were considered to be cell debris or other noise. To 
determine which cells had taken up fluorescent marker compounds (i.e., BSA, pGFP, and 
halo-tagged TALEN for uptake; PI for viability), histogram gates were set by the sham 
control which had fluorescent dyes in the solution but was not treated with 
electroporation to account for extracellular staining and other noise. To set gates and 
account for possible spectral overlap between the dyes, compensation controls were 
prepared and tested [50, 139].  
A.2 Results 
We first tested the feasibility of protein delivery into EU1 and K562 cells using 
the CytoPulse electroporator. A squarewave pulse of 1 or 2 kV/cm and fixed time of 1 ms 
was applied for the preliminary experiment on intracellular delivery of FITC-BSA. In 
EU1 cells, the delivery efficiency of FITC-BSA was similar at both pulse conditions 
(Student’s t-test, p = 0.391) at about 60% (Figure A.1, top). The cell viability decreased 
by almost 30% as the voltage increased from 1 to 2 kV/cm (Student’s t-test, p = 0.016). 
In K562 cells, the same pulse conditions resulted in different cell viability and delivery 
efficiency (Figure A.1, bottom). While cell viability did not vary significantly with pulse 
conditions (ANOVA, p = 0.276), delivery efficiency of FITC-BSA increased from 5% at 
1 kV/cm to 50% at 2 kV/cm (Student’s t-test, p = 0.002). In both cell lines, intracellular 
delivery was confirmed by fluorescence microscopy and very low fluorescence detected 
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in the control samples. These results showed that intracellular delivery of protein can be 
achieved with electroporation and the further optimization for each cell type can improve 




Figure A.1. Cell viability and delivery efficiency of FITC-BSA into EU1 cells (top) 
and K562 cells (bottom) after electroporation using the CytoPulse electroporator at 























































Once we demonstrated the uptake of FITC-BSA, we varied the pulse conditions 
with the CytoPulse instrument to examine the effect on cell viability and intracellular 
uptake. The pulse conditions were varied from 0.88 to 1.75 kV/cm with a fixed time of 5 
ms. Cell viability and delivery efficiency of FITC-BSA is summarized in Figure A.2. 
Intracellular uptake of FITC-BSA was observed at all conditions tested. However, the 
delivery efficiency was approximately 70% in the range of voltage from 0.88 to 1.25 
kV/cm, but started to decrease at higher voltage (ANOVA, p = 0.000). Cell viability also 
decreased with the increase in voltage applied (ANOVA, p = 0.000); cell viability was 
similar to the control sample at 0.88 kV/cm but decreased below 50% at 1.75 kV/cm. At 
1 kV/cm, the delivery efficiency of FITC-BSA improved significantly as pulse length 
increased from 1 ms to 5 ms (Student’s t-test, p = 0.001), while cell viability was not 
affected as much and remained similar to control samples in both cases (Student’s t-test, 
p = 0.05 and 0.07 for 1 and 5 ms, respectively). The optimized pulse conditions for 
protein delivery into K562 cells was 0.88 – 1.25 kV/cm for 5 ms.  
We also compared the result to the samples treated with the optimized condition 
(T-016) reported for the Amaxa Nucleofector II. The pulse condition of the Amaxa 
device was measured by oscilloscope and was a semi-square pulse of 0.4 kV/cm for 30 
ms. While we used a higher electric field strength for a shorter time with the CytoPulse 
instrument, the pulse condition on the Amaxa device used a lower field strength for a 
longer time. Cell viability was comparable to the control sample (Student’s t-test, p = 
0.106), but the delivery efficiency of FITC-BSA was only about 50%. Compared to the 
optimized condition using the CytoPulse instrument, the viability was slightly better 





Figure A.2. Cell viability and delivery efficiency of FITC-BSA into K562 cells at 
varying pulse conditions using the CytoPulse and Amaxa Nucleofector instruments. 
The pulse conditions tested with the CytoPulse device were treated for 5 ms. Data 
show average ± standard deviation (SD), n = 3. 
 
After optimizing the pulse conditions for FITC-BSA delivery with the CytoPulse 
device, we moved on to plasmid delivery and examined plasmid transfection efficiency 
using the optimized conditions (Figure A.3). Cell viability was similar in all samples 24 h 
after electroporation. The optimized CytoPulse conditions resulted in relatively lower 
transfection efficiency compared to the Amaxa Nucleofector (ANOVA, p = 0.000). The 
transfection efficiency using the Amaxa instrument was about 50% and similar to the 
delivery efficiency of FITC-BSA (Student’s t-test, p = 0.295). However, both pulse 
conditions with the CytoPulse instrument resulted in transfection efficiency below 20%. 
As the Amaxa nucleofector protocol is optimized for plasmid transfection, it is possible 
that the condition may be more efficient in targeting the nuclear membrane compared to 


























Figure A.3. Cell viability and plasmid transfection efficiency in K562 cells 24 h after 
electroporation with the Amaxa Nucleofector and CytoPulse instruments. Data 
show average ± standard deviation (SD), n = 3. 
 
Next, we treated the cells for intracellular delivery of proteins used in Chapter 4 
as a comparison. Although we used EU1 cells for microfluidic device and K562 cells in 
electroporation, the results of the optimized conditions may provide the sense of possible 
efficiency and viability achieved with each method. First, we quantified cell viability and 
delivery efficiency of APC in K562 cells using the optimized pulse conditions of the 
CytoPulse device (Figure A.4). We hypothesized that lower cell viability would be 
associated with higher APC concentration due to possible toxicity of intracellular APC; 
however, cell viability was similar at each condition (Student’s t-test, p = 0.164 and 
0.195 for 1 and 1.25 kV/cm, respectively). Delivery efficiency of APC increased with the 
higher concentration of APC (Student’s t-test, p = 0.001 and 0.006 for 1 and 1.25 kV/cm, 
respectively) from 30% to 50% (probably due to increased detection sensitivity of the 
stronger APC fluorescence signal) but did not vary significantly with the voltage 
(Student’s t-test, p = 0.070 and 0.113 for 0.05 and 0.1 µM APC). Successful intracellular 
uptake of APC was observed at the optimized CytoPulse conditions and the results (cell 
viability and delivery efficiency) were comparable to the microfluidic data at the same 


























Figure A.4. Cell viability and delivery efficiency of APC into K562 cells at varying 
APC concentration (0.05 and 0.1 µM) and pulse conditions (1 and 1.25 kV/cm). Data 
show average ± standard deviation (SD), n = 3. 
 
Based on previous results, we tested intracellular delivery of halo TMR-tagged R4 
TALEN into K562 cells. The same cell concentration (1 million cells/sample) and 
TALEN concentration (1 uM) was used as in the experiment with the microfluidic 
device. The control and treated samples were displayed on the histogram of the 
appropriate filter for the halo-tagged TALEN (Figure A.5). Similar to the results in the 
microfluidic devices, the control sample with halo-tagged TALEN showed a shift in the 
histogram after washing steps and was used as a basis for setting the gate for background 
fluorescence signal. While we observed two overlapping populations in the samples 
treated with microfluidic devices, we observed a shift in the histogram of the cells treated 
with electroporation, using both the Amaxa Nucleofector II and CytoPulse device. This 
indicates the intracellular uptake of halo-tagged TALEN and the efficiency was about 60 


























Figure A.5. PE channel histogram for Halo-tagged TALEN (R4) uptake into K562 
cells using the Amaxa Nucleofector and CytoPulse electroporator compared to non-
electroporated control samples. Dotted lines indicate the upper limit on the 
background fluorescence signal in control cells. 
 
A.3 Conclusion 
In this study, we demonstrated the intracellular delivery of various fluorescent 
proteins in K562 cells using electroporation. Along with the Amaxa Nucleofector, we 
tested varying pulse conditions with the CytoPulse electroporation device and identified 
optimized conditions for K562 cells with high cell viability and high delivery efficiency. 
As electroporation is used widely in many applications, the electroporation results can be 






Lipofection is a chemical intracellular delivery method and can be prepared easily 
using a number of commercially available kits. The positively charged lipid and 
negatively charged plasmid form a complex that can easily fuse with the cell membrane 
for intracellular delivery [42]. The efficient delivery of nucleic acids has been 
demonstrated in various cells types.  
In this study, we performed lipofection experiments on a hard-to-transfect 
leukemia cell line as a positive control for the plasmid transfection. In addition, the 
lipofection results are suitable to use as a standard for the optimization of nanoparticle 
experiments.  
B.1 Methods  
B.1.1 Cell culture 
Human myelogenous leukemia cells (K562, American Type Culture Collection) 
were cultured in a humidified atmosphere of 95% air and 5% CO2 at 37
◦C. K562 cells 
were cultured with RPMI-1640 medium (Cellgro, Herndon, VA), which was 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Corning, Palo 
Alto, CA) and 1% penicillin/streptomycin (Cellgro) [137, 180]. 
B.1.2 Lipofection 
Cell concentration was measured by a Multisizer 3 Coulter Counter (Beckham 
Coulter, Fullerton, CA) and prepared for the experiment at 1.5 x 105 cells per well in 24-
well plates. Lipofectamine 2000 reagent (Invitrogen, Grand Island, NY) was prepared 
according to the manufacturer’s protocol with pGFP (Aldevron). The reagents were 
prepared either in Opti-MEM medium (Invitrogen) or RPMI medium. The plasmid-lipid 
complex was added to the cells and incubated for 24 – 48 h for transfection. The cells 
were washed four times with PBS at 300 x g for 5 min after incubation. After the last 
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wash, the cells were resuspended in PBS and transferred to flow cytometry tubes for 
analysis. Propidium iodide (PI, Invitrogen) was added at a final concentration of 5 µg/ml 
10 min before flow cytometry analysis to stain non-viable cells. 
B.1.3 Analysis and quantification 
 The uptake of fluorescent dyes and cell viability were measured using a bench-top 
flow cytometer (BD LSRII, BD Biosciences, San Jose, CA). The data were collected and 
analyzed in FACSDiva software (BD Biosciences). Approximately 10,000 events were 
collected per sample. For cell viability, PI was analyzed using a PerCP-Cy5, 670 nm 
longpass filter for emission. The transfection of pGFP was measured by a FITC, 530/30 
nm bandpass filter for emission.  
B.2 Results 
Among a number of commercially available kits for lipofection, we observed the 
highest efficiency of plasmid transfection in our cells using our conditions with 
Lipofectamine 2000 from Invitrogen. We tested two variables (amount of Lipofectamine 
2000 reagent, and medium) in the study to examine the effect on cell viability and 
transfection efficiency. The amount of reagent was varied according to the range 
provided by the protocol. The media tested were Opti-MEM, which was recommended in 
the protocol, and RPMI, which was used for the culture of K562 cells. Two variables did 
not have a significant effect on the cell viability (ANOVA, p = 0.005) and cell viability 
was above 90% after 24 h incubation (Figure B.1, top). However, the transfection 
efficiency of pGFP (Figure B.1, bottom) was higher when Opti-MEM was used 
compared to when RPMI was used (Student’s t-test, p < 0.05). The transfection efficiency 
also increased slightly with an increasing amount of Lipofectamine reagent added 
(ANOVA, p = 0.033 and 0.016 for Opti-MEM and RPMI, respectively). While successful 
transfection was observed, the efficiency only ranged from 20 to 30% in K562 cells. 
Further optimization of the method would be challenging since the number of variables in 
lipofection is limited. 
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Figure B.1 Cell viability (top) and transfection efficiency of pGFP (bottom) in K562 
cells with varying amount of lipofectamine 2000 reagent. Data show average ± 
standard deviation (SD), n = 3. 
 
B.3 Conclusion 
 In this study, we performed a lipofection experiment on K562 cells to study the 
effect of medium and amount of Lipofectamine reagent on cell viability and transfection 
efficiency of pGFP. The maximum transfection efficiency achieved was approximately 
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